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Isolation and Engineering of a High Affinity Antibody Against P-selectin
Glycoprotein Ligand-1 (PSGL-1)
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Jeffrey Seth Swers
Submitted to the Department of Chemical Engineering on February 18, 2005
in Partial Fulfillment of the Requirements for the Degree of Doctor of
Philosophy in Chemical Engineering
We aim to develop novel protein antagonists of P-selectin adhesion as anti-
inflammatory therapeutics. Blocking P-selectin adhesion is particularly attractive because
this adhesion mediates leukocyte rolling which occurs early in the inflammatory cascade
before extensive tissue damage caused by the amplification of inflammation by pro-
inflammatory cytokines. Currently, no subnanomolar antagonists of selectin adhesion are
available. The low affinity of current antagonists results in the need for frequent
administration and large doses in order to obtain inhibition. High affinity antagonists are
desirable because they can be administered in smaller amounts thus reducing the risk of
harmful side effects and reducing production costs.
Our approach for developing high affinity antagonists is to combine error prone
PCR and in vivo homologous recombination to mimic in yeast the broad spectrum of
mutagenic strategies exploited by B cells such as somatic hypermutation, receptor
revision (VH CDR replacement), receptor editing (chain shuffling), and amino acid
insertions and deletions. Together with yeast surface display and flow cytometric
screening (FACS), this approach has been used to effect at least a five order of magnitude
affinity improvement in a single chain antibody (scFv) directed against the N-terminal 19
amino acids of P-selectin glycoprotein ligand- 1 (PSGL- 1).
Three rounds of engineering were performed after an initial pool of binders was
isolated from a non-immune scFv library. Chain shuffling was found to be important for
generating an improved mutant in the first round of engineering. For the final round of
engineering, four different libraries were generated: one with random mutations, one with
preferential replacement of the VH CDR1, one with preferential replacement of the VH
CDR1 and the VH CDR2, and one with preferential replacement of the light chain. All of
these methods produced two order of magnitude affinity improvements except the light
chain exchange library. However, the CDR exchange libraries gave equivalent affinity
improvement despite the fact that they were 77 fold smaller than the random mutagenic
library. In addition, an insertion in CDR2 of the VH was isolated in the best binder from
both of the CDR exchange libraries and this mutation could not have been found through
random mutagenesis. These results suggest that chain shuffling is best used when the
affinity of the antibody to be matured is weak (> 1 uM). In addition, receptor revision is
an equally robust method as random mutagensis for the generation of ultra-high affinity
binders. The best antibody from the library with preferential replacement of VH CDR1
and VH CDR2 was converted to an IgG and characterized. It was found to better inhibit
P-selectin binding to PSGL-1 than the commercially available antibody KPLI in a static
adhesion assay and an in vitro rolling assay. Our integrated approach, made possible by
in vivo homologous recombination in yeast, decreases the likelihood of convergence upon
2
a single high affinity solution and increases the probability of obtaining an antibody with
desired secretory properties and therapeutic potential. This facile method for combining
all the mutational strategies used in nature should prove as a valuable tool in the antibody
engineering field.
Thesis Supervisor: K. Dane Wittrup
Title: J.R. Mares Professor of Chemical Engineering, and Bioengineering
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Chapter 1: Introduction
1.1 Technologies for Antibody Isolation and Engineering
Because molecular recognition is at the heart of biological processes, specificity
and affinity are vital considerations for the development of therapeutic and diagnostic
agents. Therapeutic applications require a specific interaction to be blocked and for the
blocking agent to bind long enough to get a beneficial effect. Because we lack sufficient
understanding of molecular interactions, de novo synthesis of binders is often difficult or
impossible. Small molecules are the usual target of molecular design but, in general, they
are not large enough to possess the level of interaction necessary for high affinity
(subnanomolar) binding. In addition, their small size can lead to toxicity issues. Proteins
are much larger entities with the potential for high specificity because of their large
surface area and low toxicity because they are composed of the same building materials,
amino acids, that are used within the human body. However, our understanding of
protein folding and protein-protein interactions is not sufficient to rationally design novel
protein binders.
Fortunately, evolution has provided an answer to the question of how to develop
proteins with novel specificities. That answer is the antibody. Through their CDRs
(complemetarity determining regions), antibodies can bind to virtually any antigen that
exists. Their highly stable scaffold is compatible with CDRs of varying length and
composition and the immune system has the ability to generate a large primary repertoire
of 3.5 * 106 if only combinatorial joining of V-J and V-D-J segments is considered'.
Including other mechanisms of diversity generation such as nucleotide addition between
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the V-J and V-D-J segments, the diversity of the human primary antibody repertoire is
estimate to exceed 1010 2. In addition, the human immune system can further enhance
antibody specificity and affinity in the periphery through somatic hypermutation, amino
acid insertion and deletion3 -5, switching of light chains (receptor editing)6 -8, and exchange
of portions of the variable region of the heavy chain (receptor revision)9 ' 1o.
The traditional methods of developing an antibody against a given target is to
inject the target into an animal and either harvest the antibodies it creates or create
monoclonal antibodies using hybridoma technology. Non-human antibodies present the
problem that they will elicit an immune response when injected into a human. Because
most therapeutic targets are human and a human cannot mount an immune response to a
human protein, various methods have been generated to overcome this difficulty. To
reduce the non-human content in an antibody, the entire variable region of a non-human
antibody can be grafted onto a human constant region to generate a chimeric antibody.
Furthermore, the non-human CDRs can be grafted onto a human antibody to create a
humanized antibody.
Various methods have been developed to isolate fully human antibodies.
Transgenic mice in which the mouse V-genes are replaced with human V-genes have
been generated 1-13. Although antibodies obtained from these mice can be useful without
further manipulation, if their properties need to be modified they must be cloned into
another system for further engineering. Technologies that do not require the need for
immunization are available such as phage display 4 ' 15, yeast surface display 6' 7, and
ribosome display'8' 19. Phage display is the 'gold standard' for directed evolution of
proteins because it has been around for the longest period of time20. Phage display
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involves the fusion of a human antibody fragment to a phage surface protein, commonly
pIII. There are usually one to three antibody fragments displayed per phage particle.
Binding antibodies are found by panning the phage library against an antigen coated on a
surface. Non-binders are washed away and the phage that bound are used to infect
bacteria. The resulting phage can be harvested and further used for panning.
Yeast surface display involves the fusion of a single chain antibody (scFv) to the
yeast surface mating receptor (Figure 1.1). There are thousands of antibody fragments
displayed per cell in contrast to the one to three antibody fragments displayed per phage
particle. Antigens coupled to fluorescent dyes can bind to the antibody fragments on the
yeast surface thereby allowing for the detection and recovery of yeast cells encoding
binders by using a fluorescence activated cell sorter, also know as FACS (Figure 1.2).
Yeast display has many important advantages. First, it is a eukaryotic expression system
and has foldases and chaperones making it more suitable for producing human proteins
such as antibodies. In addition, the quantitative nature of the FACS screening process
ensures that the antibodies are well expressed in yeast21. Poorly expressed clones will not
be isolated because a minimum threshold fluorescence is necessary for a cell to be
detected and sorted. Moreover, quantitative screens allow for fine affinity discrimination
between clones that is not possible through panning.
1.2 A Non-immune Antibody Library in Yeast
Although antibodies have been engineered in yeast with great success2 2, it was
only recently that a yeast surface displayed, human, non-immune library was made
available for the isolation of antibodies with novel binding specificities'7. This library is
approximately of 1.0 * 109 diversity and was made from PCRing spleen and lymph node
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mRNA using IgG and IgM heavy chain primers and A and K light chain primers (Figure
1.3). Binders were obtained against protein, peptide, and hapten antigens. This library
has the advantage of being able to be propagated without an expression bias because the
yeast promoter is tightly regulated. This promoter is galactose inducible and proteins that
are deleterious to host growth can be maintained in the binding pool when the yeast are
grown on glucose.
1.3 Yeast Surface Display: New Opportunities for Antibody
Engineering
As previously described, yeast surface display has been proven as a method for
antibody engineering and isolation. However, the flexibility provided by the yeast host
can serve as a basis for advancing the way in which antibodies are engineered for higher
affinity binding. For example, antibody engineering is usually performed in an iterative
manner in which a method for diversity generation, such as random mutagenesis, CDR
saturation mutagenesis, gene shuffling, or a combination of these methods is used
followed by selection and repeated until an antibody of a desired affinity is isolated.
However, this method does not exactly mimic how antibodies are affinity matured in
vivo. Random mutagenesis does emulate somatic hypermutation but other in vivo
methods are not readily used for antibody engineering. In the periphery, light chain
shuffling, amino acid insertions and deletions, and receptor revision occur to further
diversify antibodies. Although previous attempts have been made to mimic receptor
editing and receptor revision using phage display, yeast greatly simplifies the way in
which these methods can be used. The key simplification is the ease of which yeast
recombine single stranded DNA that have stretches of homology. Those who work in
phage must use more laborious methods, such as site specific recombination, which are
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time consuming and limit diversity by confining crossover sites to specific regions.
Utilizing yeast homologous recombination allows for one to easily mimic affinity
maturation as it actually occurs in the human periphery and this simplification is the basis
for Chapters 2 and 3 of this thesis.
1.4 Yeast Surface Display for the Isolation and Engineering of an
Antagonist of P-selectin Adhesion to PSGL-1
In order to demonstrate the powerful new techniques for antibody engineering
made possible through yeast surface display, we have chosen to isolate and engineer, in a
way never previously attempted, a fully human antibody directed against P-selectin
glycoprotein ligand-1 (PSGL-1). PSGL-1 is an important therapeutic target because it is
the only physiologically relevant ligand for P-selectin known23 . P-selectin binding to
PSGL-I is the first step in the process of how leukocytes migrate out of blood vessels
into the surrounding tissue during an inflammatory response. The N-terminal nineteen
amino acids of PSGL-1, which contain three potential sites of tyrosine sulfation and one
O-linked site of glycosylation, have been shown to be necessary and sufficient for
mediating adhesion with P-selectin in vivo24. The O-linked glycosylation contains sialyl
Lewis X (s-Lex) which is a tetrasaccharide that has been shown to bind P-selectin with a
very weak affinity (Kd = 7.8mM)2 5. P-selectin, however, binds PSGL-1 with a Kd of 320
+ 20 nM26 . As the crystal structure reveals, the increased binding affinity of P-selectin
for PSGL- can be explained by the fact that at least two of the PSGL-I sites of tyrosine
sulfation are important for binding in addition to the s-Le x 27. Interestingly, PSGL-1 is a
minor glycoprotein on myloid cells representing less than 1% of the surface s-Lex
however it is vital for P-selectin specific binding28. This fact makes PSGL-1 a more
attractive target than s-Le because a PSGL- blocker could be dosed in lower quantities.
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In addition, s-Lex is involved in other functions such as leukocyte homing, thus, binding
to PSGL-1 may be less likely to produce harmful side effects.
Upon exposure to certain pro-inflammatory mediators such as histamine, P-
selectin is expressed on the endothelial cell surface within minutes. A drawing of the
rolling along the endothelium mediated by P-selectin/PSGL-1 interactions is shown in
Figure 1.4. This rolling is believed to activate the neutrophil so that it can firmly adhere
to the endothelial cell surface. Firm adhesion is mediated by a different class of proteins
known as integrins (Figure 1.5). After firm adhesion, the cell extravasates into the
surrounding tissue. Each step in inflammation is accompanied by a release of cytokines
that further amplifies the response. Blocking P-selectin adhesion is particularly attractive
because leukocyte rolling occurs early in the inflammatory cascade before extensive tissue
damage caused by the amplification of inflammation by pro-inflammatory cytokines.
A high affinity antagonists of P-selectin adhesion has the potential to have a major
impact on the treatment of both acute and chronic inflammation. Treatment of diseases
such as inflammatory bowel disease, ischemia/reperfusion injury, hemorrhagic shock,
restenosis subsequent to angioplasty, asthma, and arthritis could be greatly advanced by
such an intervention. Steroids, the major drug used to fight inflammation, are beneficial
for reducing symptoms but can produce harsh side effects that are as intolerable for the
patient as the illness being treated. High affinity antagonists may reduce inflammation at
a dosage below which intolerable side effects are evident. The search for high affinity
selectin inhibitors as anti-inflammatory therapies is so important that noted glycobiologist
Ajit Varki of the University of California, San Diego has termed their development as
one of the "Holy Grails" of the selectin field23.
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1.5 Thesis Overview
The second chapter of this thesis focuses on the development of a technique for
utilizing homologous recombination in yeast for the creation of large, shuffled antibody
libraries. The third chapter describes the isolation of a pool of novel scFvs that bind to
PSGL-1. This chapter next explains how this pool of binders was used to create a single
scFv and then describes how this scFv was affinity matured using a variety of techniques
that mimic affinity maturation in the periphery of the human immune system. The fourth
chapter describes the conversion of one of the highest affinity scFvs developed to an IgG
and then shows that this antibody is more effective at blocking leukocyte rolling than a
commercially available mouse monoclonal antibody known as KPL 1.
14
Figure 1.1: Schematic representation of an scFv displayed on the yeast's surface. The
scFv is flanked by two epitope tags, an HA tag 5' to the scFv and a c-myc tag 3' to the
scFv. The c-myc tag allows for normalization for protein expression. A bound
biotinylated ligand can be detected by using fluorescently tagged streptavidin, such as
streptavidin-phycoerythrin (PE).
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Figure 1.2: Schematic representation of a fluorescence activated cell sorter (FACS).
Cells pass by an argon laser and the fluorophores bound to the cell surface are excited.
The emission is detected by the appropriate detector and can be displayed on a computer
in various formats. The bivariate histogram shows the FL2 signal, which corresponds to
PE fluorescence, plotted against the FL1 signal, which corresponds to fluorescein
isothiocyanate (FITC) fluorescence. The desired cells can be sorted by drawing a gate on
the bivariate histogram. This figure is adapted from Graff (2002)29.
16
545 nm
ilI
a 
10
ts:
m
x)
PE
Positive
102-
Double
. Positive /
Sort
Gate
U
R5 FITC
Positive
101.
10n
l10 I10.3 104
ME
·
103-
1
JU Kd.
m
W
8 x 107 clones
POR
IcG and IgM
heavy chain
/
plri
spleen and
lymph node
mRNA from
58 adults
6
Yeast '
'N\ trnfrnrmntinn
1.2 x 106 clone
1 * 109
r'Irnn~c
an.,1 l I I. I I ds.l
and display P
ing plasmid
,#
/
PCI
chr
pri
Figure 1.3: Schematic representation of the yeast surface displayed non-immune
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Figure 1.4: Diagram of selectin mediated rolling of leukocytes along the vascular
endothelium. The leukocytes are shown with glycoproteins containing the sugar sialyl
Lewis X (s-Lex) of which PSGL-I is one example. This picture is taken from Janeway
(1999)'.
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Figure 1.5: Leukocyte rolling is followed by firm adhesion of the leukocyte to the
endothelium. In this picture E-selectin is shown however P-selectin also mediates
rolling. LFA-1 is an integrin that binds to ICAM- allowing for firm adhesion of the
leukocyte to the endothelium. Adhesion is followed by extravasation into the
surrounding tissue. This picture is taken from Janeway (1999)1.
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Chapter 2: Shuffled Antibody Libraries Created
by In Vivo Homologous
Recombination and Yeast Surface
Display*
2.1 Introduction
Various methods have been developed for the creation of diversity within protein
libraries including random mutagenesis 30-32 in vitro DNA shuffling 33' 34, and site-
specific recombination 35-38. Random mutagenesis techniques utilize either a non-proof
reading DNA polymerase in the presence of MnC12 39, mutator Escherichia coli strains 16
or nucleotide analogues that cannot be correctly read by the DNA polymerase 40
Random mutagenesis has the advantage of allowing for the isolation of beneficial
mutations anywhere within the gene that may not be obvious a priori. However, point
mutation methods do not allow for a radical restructuring of the contact regions and
therefore are restrictive in the sequence space that can be probed. DNA shuffling
methods have the advantage of being able to generate hybrid genes that contain portions
of sequence space that have already proven to be functional. DNA shuffling consists of
four steps: a DNase I digestion of the genes to be recombined, a PCR reassembly without
primers, an amplification of recombined gene products of the correct size from the
primerless PCR pool, and a ligation of the reassembled product into an acceptor vector.
Although DNA shuffling has proven to be a highly effective method, numerous PCR and
associated purification steps are required. Site specific recombination has the advantage
of utilizing portions of known sequence space that have already proven functional, but it
is often an impractical method because it requires the engineering of restriction enzyme
*This chapter is based upon Swers, J.S., Kellogg, B.A. & Wittrup, K.D. Shuffled
antibody libraries created by in vivo homologous recombination and yeast surface 20
display. Nucleic Acids Res 32, e36 (2004).
sites into the genes to be combined. Often finding unique sites is difficult and the process
can become tedious when multiple chimeric products are desired. Other forms of site
specific recombination have been used to make libraries such as the n-CoDer antibody
library in which CDRs were shuffled using specific primers and PCR reassembly 41,
chain shuffled scFv libraries in which the shuffling was performed by PCR utilizing
homology in the linker region between the heavy and light chains 42, and chain shuffled
antibody libraries using Cre catalyzed recombination of antibody heavy and light chains
that are flanked by lox sites 37 38 In all of these libraries the points in which gene
exchange occur are fixed and prior knowledge of the gene sequences for the creation of
PCR primer sets or engineering of specific sites is required.
A simple method for creating hybrid genes that does not require the extensive
PCR steps of DNA shuffling, the pre-engineering of site-specific recombination methods,
or ligation would be desirable. In this paper, we present a technique for creating large,
chimeric antibody libraries using plasmid reconstruction by homologous recombination
in the yeast Saccharomyces cerevisiae 43', 44. This method allows for the coupling of
diversity generation and protein production within the host organism rather than having a
separate in vitro diversity generation step. In vivo recombination in yeast has been used
in the past to create hybrid genes 4547 and has been successfully used to generate a library
for the directed evolution of a heme peroxidase enzyme 47. However, this technique has
not been exploited for the generation of antibody libraries. This absence can be
explained by the fact that most in vitro antibody engineering is performed using phage
which relies upon the machinery of E. coil for gene propagation and protein production.
Although intra (Figure 2. 1A) and inter-molecular recombination (Figures 2.1 B and 2.1C)
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have both been performed in E. coli to make hybrid genes, inter-molecular recombination
has generally been used for plasmid construction and not recombination 48. Inter-
molecular recombination is inherently more flexible than intra-molecular recombination
because only one (Figures 2.1B and 2.1C) or none (Figure 2.1D) of the genes to be
recombined must be within a vector while intra-molecular recombination requires both
genes to be within the same vector. The most flexible scheme, presented in Figure 2.1 D,
allows for recombination anywhere in the genes to be shuffled and is most applicable to
antibody engineering because none of the genes must be within the acceptor vector.
Thus, pools of antibodies can be shuffled with no bias towards any individual acceptor
antibody. To our knowledge, the crossover scheme depicted in Figure 2. lD has not been
used to generate antibody libraries in E. coli. This fact can be explained by the
proficiency of Saccharomyces cerevisiae in homologous recombination in comparison to
the inherent problems in the endogenous E. coli homologous recombination mechanism
49. For example, the E. coli endogenous homologous recombination mechanism is
initiated by the cooperation between RecA and the enzyme RecBCD which impedes the
use of linear DNA because RecBCD is a vigorous exonuclease 49. In the cases where
E.coli has been used to create hybrid genes (Figures 2.lB and 2.1C) mutant strains must
be used which are not advantageous because they can exhibit genetic instabilities during
library transformation and propagation. Although it is possible to exploit the yeast
recombination method to make chimeric genes and then recover the plasmids containing
the hybrid gene products for transfer to E. coli, this method is hampered by both the
inefficient recovery of plasmids from yeast minipreps and the added difficulty of having
to switch hosts. Not until the advent of yeast surface display did it become practical to
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exploit yeast in vivo homologous recombination methods for making chimeric antibody
libraries.
This paper is the first report of in vivo homologous recombination for the creation
of large, yeast surface displayed antibody libraries. Yeast surface display has already
proven a powerful tool for affinity maturation by mutagenic PCR of antibodies 16, 31 and
T-cell receptors 32 and recently has been shown to be a valuable tool for the isolation of
antibodies with novel specificities 50. Here, we demonstrate that homologous
recombination shuffling in conjunction with yeast surface display greatly simplifies the
creation of large, chimeric antibody libraries. First, we show that homologous
recombination by electroporation reliably generates yeast surface displayed libraries of
107 clones and eliminates the need for a ligation step and an E. coli cloning step. Next,
we use two scFvs that share 89.8% homology between them as a test case to demonstrate
that yeast can shuffle genes in vivo by homologous recombination. The technique
presented in this paper requires fewer PCR cycles than in vitro DNA shuffling, does not
require a ligation step, and, unlike site specific recombination methods, it allows for
recombination anywhere homology exists between the genes to be recombined.
Moreover, the diversity generated is not limited to single crossovers, hybrid antibodies
created by double and triple crossovers were easily obtained. This technique should
prove to be an important addition to the aforementioned methods for the isolation of
affinity improved antibodies.
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2.2 Materials and Methods
2.2.1 DNA Preparation for Homologous Recombination
The two scFvs used in the shuffling experiments were isolated from a previously
constructed yeast surface displayed nonimmune library 50. To test homologous
recombination frequencies of a mutagenic PCR product, a third scFv from this library
was amplified in a PCR reaction using a nucleotide analogue mutagenesis procedure that
has been previously described 40. All PCR products were inserted into the vector
PCTCON 50 which had been restriction digested from NheI to BamHI (New England
Biolabs) and gel purified using a gel purification kit (Qiagen) according to the
manufacturer's instructions. As described in Raymond, Pownder and Sexson, to obtain
the best transformation efficiency, homologous recombination primers were designed so
that the inserts would have approximately a 50 basepair overlap on each end with the cut
acceptor vector 44. The primer used to make inserts with 5' homology to the cut vector
was 5'-
CGACGATTGAAGGTAGATACCCATACGACGTTCCAGACTACGCTCTGCAG-3 '
and the primer used to make inserts with 3' homology to the cut vector was 5'-
CAGATCTCGAGCTATTACAAGTCTTCTTCAGAAATAAGCTTTTGTTC-3'. To
make either scFvl or scFv2 which lacked 5' homology to the cut vector the primer 5'-
GCTAGCCAGGTACAGCTGCAGC-3' was used and to make either scFvl or scFv2 that
lacked 3' homology to the cut vector the primer 5'-
AATTCCGGATAGGACGGTGAGCTTGG-3' was used. All oligonucleotides were
obtained from MWG-Biotech. PCR reactions were carried out on a Perkin Elmer DNA
Thermal Cycler 480. A typical PCR reaction was carried out in a 100 uL volume using
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10-100 ng of template, 1 /uM primers, 0.2 mM of each dNTP, 6.25 U Taq (Invitrogen),
and 2 mM MgC12. The cycling conditions used were 1 cycle of 94°C for 1 minute
followed by 35 cycles of 94°C for 1 minute, 50°C for 1 minute, 720C for 2 minutes,
followed by 1 cycle of 72°C for 10 minutes. PCR products were gel purified using a
Qiagen kit. Insert fragments were concentrated with Pellet Paint (Novagen) to a
concentration of 5 pg/ul according to the manufacturer's instructions and cut backbone
was likewise concentrated to a concentration of 1 ug/ul.
2.2.2 Preparation of Electrocompotent Yeast for Homologous Recombination
The method of yeast preparation closely follows the one described by Meilhoc,
Masson, and Teissid 51. First, 50 ml of YPD was inoculated with the Saccharomyces
cerevisiae strain EBY100 16 to OD 0.1 from an overnight culture of EBY100 in YPD.
Next, the cells were grown with shaking at 300C to an OD of 1.3 to 1.5 (about 6 hours of
growth). The cells were harvested by centrifugation and resuspended in 50 mL of freshly
prepared 10 mM tris, pH 8.0, 25 mM dithiothreitol (DTT) in YPD and shaken for 20
minutes at 300 C. The cells were washed once with 25 ml E buffer (10 mM tris, pH 7.5,
270 mM sucrose, I mM MgCI2) and again with 5 ml of E buffer. Finally, cells were
suspended in buffer E to give 2 * 108 cells per 50 ,ul aliquot.
2.2.3 Homologous Recombination Protocol
The ratio of total insert fragment to cut acceptor vector was maintained at 10:1 for
all transformations. For shuffling experiments where both scFvs were transformed
together, half of the insert fragment pool consisted of one scFv and half of the insert
fragment pool consisted of the other. One ug (1 ul) of cut acceptor vector and 10 pg (2
,ul) of insert were added to a 50 ,ul aliquot of electrocompotent yeast and incubated on ice
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for 5 minutes. Electroporation was carried out using a Biorad Gene Pulser with a 0.2 cm
cuvette (voltage = 0.54kV, capacitance = 25 OF) giving a time constant of about 18 ms.
After pulsing, the cell aliquots were transferred to 1 ml of YPD media and incubated for
1 hr at 30°C . Cells were then harvested at 3500 rpm for 4 minutes and resuspended in
SDCAA selective media (-Ura, -Trp). A small aliquot of cells was removed and plated
on SDCAA plates to determine transformation efficiency.
2.2.4 DNA Isolation and Sequencing
Colonies from the SDCAA plates were grown in 5 mL of SDCAA overnight and
the DNA was isolated using a Zymoprep kit (Zymo Research) according to the
manufacturer's protocol. Two ul of Zymoprep DNA were used in an XL1-Blue
(Stratagene) E. coli transformation according to the manufacturer's instructions. Cells
were plated on selective LB plates supplemented with 100 mg/L ampicillin. Colonies
from these plates were grown overnight at 370 C in LB media plus 100 mg/L ampicillin
and DNA was isolated using a Qiagen miniprep kit according to the manufacturer's
instructions. DNA was sequenced on a Applied Biosystems model 3730 DNA sequencer
using version 3.0 Big Dye chemistry.
2.3 Results
2.3.1 Creation of Large Yeast Surface Displayed Libraries by Homologous
Recombination
As has previously been reported, the yeast S. cerevisiae is highly efficient at
reconstructing plasmids from a linearized plasmid and a PCR product that contains
sufficient homology on the 3' and 5' ends 43 44. Figure 2.2 outlines the homologous
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recombination strategy. The first step involves the linearization of a yeast surface display
plasmid, which contains an irrelevant gene flanked by a 5' NheI site and a 3' BamHI site,
in a restriction digest. The second step involves the creation of a pool of PCR fragments
that share 5' and 3' homology to the cut display vector. Because Raymond, Pownder, and
Sexson report that overlaps of 50 basepairs on each end of the PCR product yield the
highest number of recombinants 44, we made PCR fragments of mutagenic antibody
library DNA that have approximately 50 basepairs of homology to the display vector on
their 5' and 3' ends. Cotransformation of these fragments with linearized plasmid
allowed for the creation of large yeast displayed libraries. Table 2.1 shows the results of
two different transformations of mutagenic antibody library DNA using homologous
recombination. Both experiments yielded a transformation efficiency of order of
magnitude 105 per microgram of insert DNA. Homologous recombination by
electroporation simplifies library generation by completely eliminating the need for
ligation of PCR products into a cut vector and the subsequent cloning into E. coli.
Library sizes of 107 are routinely achieved without great effort.
2.3.2 In Vivo Shuffling of Antibody DNA by Homologous Recombination
It is our desire to extend the technique of homologous recombination in yeast to
allow for the easy construction of chimeric scFv antibody libraries. To test if chimeras
can be created by homologous recombination, a series of four different transformation
experiments (Figure 2.3) were performed using two different antibodies, termed scFvl
and scFv2, which shared 89.8% homology between them. These antibodies, which were
isolated from a nonimmune S. cerevisiae displayed library 50, were chosen not only
because they shared significant patches of homology but also because they had numerous
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differences spread throughout the entire length of their sequences (Figure 2.4). These
differences are critical for the determination of crossover points. In the experiments
depicted in Figures 2.3A and 2.3B, the two genes to be recombined had homology with
the linearized display vector at one end only. In principle, neither fragment alone could
recreate a whole plasmid because each fragment was missing critical homology on one
end. Therefore, only recombinants would be isolated after transformation. To determine
if forcing recombination is necessary for the creation of hybrid genes, a third experiment
was performed (Figure 2.3C) using scFvl and scFv2 where both genes contained 5' and
3' homology to the display vector. In a fourth experiment (Figure 2.3D), scFvl was
transformed alone to verify that both 5' and 3' homology are necessary for plasmid
reconstruction.
Figure 2.4 shows the results of the in vivo homologous recombination shuffling
experiments. For all of the results depicted in Figure 2.4, the crossover point in the
chimeric antibody sequence was determined to be the last nucleotide of homology 5' to a
difference between the chimeric antibody sequence and whichever scFv sequence to
which the chimeric antibody had homology up till that point. Because scFvl and scFv2
share sixty basepairs of homology at the beginning of their sequences and forty four
basepairs of homology at the end of their sequences, it is possible for crossovers in these
regions to generate genes that have 100% sequence identity to one of the two original
scFvs. It was our initial hypothesis that for the insertion into the display vector to be
successful, the insert fragment needs both 5' and 3' homology to the cut plasmid.
However, the results depicted in Figure 2.4D indicate that this hypothesis is false because
ten of the twelve clones sequenced were 100% homologous to scFvl although scFvl
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lacked the 5' homology necessary for in vivo homologous recombination to occur.
Apparently, the single stranded end of the NheI cut plasmid can recombine with the
blunt, double stranded DNA of the scFv to be inserted. It is likely that the BamHI cut
end of the vector can also recombine with blunt end DNA in a similar manner. This
integration phenomena might be a form of illegitimate integration, defined as
recombination involving little or no sequence homology, that has been previously
reported to occur in S. cerivisiae 52. Thus, it is impossible to tell if a gene that has 100%
homology to either scFvl or scFv2 is a hybrid or was generated through illegitimate
integration. In this paper only genes that clearly contain portions of scFvl and scFv2 will
be considered to be chimeric.
Figure 2.4A (corresponding to the experiment depicted in Figure 2.3A) shows that
of the forty eight clones sequenced, twelve were chimeric and Figure 2.4B
(corresponding to the experiment depicted in Figure 2.3B) shows that of the forty six
clones sequenced, seventeen were chimeric. It is not surprising that all of the hybrids in
Figure 2.4A shared homology 5' to the crossover point with scFv2 and homology 3' to
the crossover point with scFvl because in this experiment scFv2 had 5' homology to the
cut plasmid and scFvl had 3' homology to the cut plasmid. As expected, the reverse is
generally true for the experiment depicted in Figure 2.3B. We see that in all but two
cases (clones 23 and 24) the chimeric clones shared homology 5' to the crossover point
with scFv 1 and homology 3' to the crossover point with scFv 2 (Fig. 2.4B). Clones 23
and 24 may have been generated by a crossover event in the first sixty basepairs or may
be the result of illegitimate integration. Figures 2.4A and 2.4B indicate that the crossover
points are evenly distributed in the hybrids created. Only clones 6 and 18, generated by a
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crossover point immediately 5' to CDR3 of the heavy chain, were found at a slightly
higher frequency than other chimeras (three times and five times, respectively, in
comparison to approximately one occurrence per chimera for the other hybrids).
In Figure 2.4C (corresponding to the experiment depicted in Figure 2.3C), only
five of forty six clones sequenced were chimeric. Thus, it appears that forcing the
recombination as in the experiments depicted in Figures 2.3A and 2.3B yields a higher
frequency of chimeras than when both genes can recombine with the cut vector at both
their 5' and 3' ends. The presence of light chain only inserts (clones 33, 34 and 36) is
not surprising when one considers that every scFv contains a fifteen amino acid linker
consisting of three repeats of four glycines and a serine ((gly4ser)3) that joins the variable
heavy and variable light domains. This same linker is present immediately 5' to the gene
in the display plasmid and these linkers share 80% sequence homology. It is surprising
that these clones were not found in the other two libraries, although there is every reason
to believe that further sequencing would reveal the presence of light chain only insertions
in both cases. It is important to note that clone 31 resulted from a crossover in a region of
two basepairs of homology, indicating that on rare occasions crossovers can occur in
regions of very limited homology. This result is in agreement with that found by Mezard,
Pompon, and Nicolas 45 and demonstrates that the power of this technique is not limited
by the need for long stretches of homology between the genes to be recombined.
Double (clone 24 and 32) and triple (clone 11 and 25) crossovers greatly increase
the diversity potential of libraries generated by in vivo homologous recombination. To
estimate this diversity, we applied the Poisson distribution to estimate the probabilityp of
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obtaining a clone with x = 0,1,2... crossovers in a given sequence by using the following
equation:
p(x;) e 2.1
where A is defined as the average number of crossovers per sequence in a given
experiment. The value of A was 0.29 in the experiment depicted in Figure 2.3A, 0.43 in
the experiment depicted in Figure 2.3B, and 0.13 in the experiment depicted in Figure
2.3C. For each of these experiments the expected and actual number of clones obtained
are listed in Table 2.2. As one can clearly see, the number of clones experimentally
obtained for x = 0 or x = I is well approximated by the Poisson distribution. The limited
sampling size of between forty five and fifty clones per experiment explains the lack of
agreement for x = 2 and x = 3. Table 2.3 gives the expected number of clones containing
a given number of crossovers for a I * 107 library. Although this table gives a picture of
the distribution of crossovers, it does not take into account the number of unique
sequences which is the true measure of library diversity. The following equation can be
used to determine the number of unique sequences, u, obtained with a given number of
crossovers x when y genes are crossed:
Au = y(y (z- Xj 2.2
zl A
where x! ( indicates the number of combinations with z crossover points. As
shown in Table 2.3, for a cross of two genes with an arbitrarily chosen number of twenty
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distinct crossover points this equation yields 40 unique one crossover clones, 380 unique
two crossover clones, and 2280 unique three crossover clones. The data in Table 2.3
reveals the trend that the number of unique clones with multiple crossovers will become
greater than the number of clones predicted to have multiple crossovers by a Poisson
distribution as the number of genes crossed is increased. For crosses of small numbers
of antibodies, the chimeras in the library created would be dominated by many copies of
each unique single crossover clone but the added diversity created by double and triple
crossovers would be nonzero. For a cross of one hundred genes, the potential theoretical
diversity would be dominated by unique multiple crossover clones and would greatly
exceed the diversity of multiple crossover clones predicted to be in the library by the
Poisson distribution, however, the unique single crossover clones would still be
oversampled in a I * 107 library. In addition, the number of double and triple crossover
clones as predicted by the Poisson distribution, 77910, is 39% of the maximum number
of unique single crossover clones, 198000, indicating that double and triple crossovers
are a nontrivial component of the total diversity. Of course, clones with four or more
crossovers may exist, but because none were isolated in the limiting sampling of this
experiment they were not included in the analysis.
The possibility that forcing recombination reduced transformation efficiency
below a level that was useful was considered. However, for all of the crosses performed
here the transformation efficiency was of order 104 to 105 per microgram of insert. Thus,
forcing recombination does not appreciably affect transformation efficiency.
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2.4 Discussion
In this paper, we present a simple method for reliably producing large, yeast
surface displayed chimeric antibody libraries. This method takes advantage of the
homologous recombination pathway in yeast to reconstruct full plasmids from restriction
digested plasmids and PCR products that have 5' and 3' homology to that cut plasmid.
Transformation of multiple PCR products that share homology can cause recombination
events to yield chimeric gene products. Forcing recombination by making a PCR product
of one gene with 5' homology to a cut vector and making a PCR product of a second
gene with 3' homology to a cut vector yields greater numbers of chimeric gene products
than when both genes to be recombined share both 5' and 3' homology to the vector into
which they are to be inserted. The transformation efficiency for forced recombination
was not appreciably lower than that of a single PCR product with both 5' and 3'
homology to the cut display plasmid.
Although forced recombination yields the greatest number of hybrid genes, this
method may prove impractical because one must know the sequence of the 5' or 3' ends
of the genes that are to be shuffled. In the case presented in this paper, the two genes to
be recombined had known sequences that facilitated primer design. However, one may
wish to shuffle one scFv gene against an entire library of scFvs or shuffle a batch of scFv
genes that all bind a given antigen. Generic primer sets for all antibody heavy and light
chains are known and it would be possible to force recombination by creating PCR
products that lack 5' or 3' homology to the vector into which the genes are to be inserted.
This method is rather tedious and in our experience has proven unnecessary. As our
experiments demonstrate, not forcing recombination allows for the creation of hybrid
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clones, albeit at a lower rate than forced recombination. The number of chimeric clones
obtained is only two to three fold less than in forced recombination and is therefore not
low enough to cause concern that forcing recombination is necessary for this technique to
be practical.
It is important to stress that the ability for as little as two nucleotides homology to
yield successful recombinants in conjunction with the presence of double and triple
crossovers demonstrates that this technique has a vast potential for producing highly
diverse libraries. Although it is true that most chimeras contain only one crossover, there
will still be many unique clones in the library to ensure the necessary diversity for
directed evolution experiments. It is likely that the unique diversity of libraries made by
yeast in vivo homologous recombination will be sufficient for affinity improvements even
if the actual diversity of the libraries generated is orders of magnitude lower than the total
number of transformants because the shuffling of antibodies is a rearrangement of
diversity that has been maintained specifically because it is functional. The advantage of
this technique is its simplicity and it is likely that many variations other than those
presented here will emerge for the production functional diversity in protein libraries.
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Transformation efficiencies of two different homologous recombination
experiments.
Trial Insert to Vector Micrograms of # of Transformants
Ratio Insert Transformed per Microgram
Transformed Clones of Insert
1 10:1 31 1.8 * 107 5.8 * 10
2 10:1 60 2.3 * 10' 3.8 * 10b
Expected and experimentally determined number of clones with a given
number of crossovers as predicted by a Poisson distribution.
scFvl with 3' Homology + scFv2 scFvl with 5' Homology + scFv2 scFvl with 5' and 3' Homology +
with 5' Homology with 3' Homology scFv2 with 5' and 3' Homology
Number of Actual Number of Poisson Actual Number of Poisson Actual Number of Poisson
Crossovers Sequences with Calculated Sequences with Calculated Sequences with Calculated
per x Crossovers Number of x Crossovers Number of x Crossovers Number of
Sequence Sequences with Sequences with Sequences with
(x) x Crossovers x Crossovers x Crossovers
0 36 36 29 30 41 40
1 11 10 15 13 4 5
2 0 2 1 3 1 0
3 1 0 1 0 0 0
Table 2.3: Expected number of total clones and unique clones with a given number of
crossovers as predicted by a Poisson distribution for a 1 * 107 library.
Number of Number of Number of Unique Sequences Assuming 20 Distinct Crossover Points
Crossovers Sequences with
per x Crossovers in
Sequence a 1 * 10 7 Library Recombine 2 Recombine 3 Recombine 4 Recombine 100
(x) with A = 0.13 Genes Genes Genes Genes
0 8777137 2 3 4 100
1 1144844 40 120 240 198000
2 74664 380 2280 6840 186219000
3 3246 2280 27360 123120 1.1 * 1011
Total 1 * 107 2702 29763 130204 1.1 * 1011
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Table 2.1:
Table 2.2:
A.
C.
Figure 2.1: Some common in vivo homologous recombination schemes. (A) Intra-
molecular recombination where both genes to be recombined are located within the same
plasmid. (B) Inter-molecular recombination between a gene and a similar gene that is
located within a plasmid and has been cut at an internal restriction site. The acceptor
gene within the plasmid determines he 5' and 3' ends of the gene hybrid. (C) Inter-
molecular recombination between a donor gene that contains a portion of homology on
its 3' end to the vector to which it is being inserted. The vector is cut at the 3' end of the
acceptor gene that is located within the plasmid. The acceptor gene determines the 5' end
of the hybrid gene generated. (D) Multiple gene hybrids are generated by genes that
contain homology at their 5' and 3' ends to the vector to which they are to be inserted.
Homology within the genes allows for multiple recombination events and the order of the
genes within the final hybrid is not fixed by the presence of a gene within the acceptor
plasmid. This figure is adapted from Wang 48
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PCR Products with 5' and 3'
Homology to Cut Vector Homologous Recombination Library In Display Plasmid
Transformation by · d .
ml- Electroporation
Restriction Digested 
Display Vector
Figure 2.2: General outline of library construction using homologous recombination in
yeast. First, PCR products are created with 5' and 3' homology to the vector into which
they are to be inserted. Next, the PCR products are transformed together with a
restriction digested vector by electroporation, and yeast utilizes the homology between
the cut vector and the PCR products to reconstruct whole plasmids.
37
A. B.
scFvl scFvl
scFv2 scFv2
C. D.
scFvl scFvl
scFv2 
Figure 2.3: In vivo homologous recombination experiments. (A) Homologous
recombination when scFv 1 has 3' homology to the display vector and scFv 2 has 5'
homology to the display vector. (B) Homologous recombination when scFv 1 has 5'
homology to the display vector and scFv 2 has 3' homology to the display vector. (C)
Homologous recombination when both scFv 1 and scFv 2 have 5' and 3' homology to the
display vector. Solid lines indicate a crossover producing chimeric clones that have 5'
homology to scFv 1 and 3' homology to scFv 2. Dashed lines indicate a crossover to
produce chimeric clones with the opposite arrangement. A mixed path of one solid line
crossover and one dashed line crossover without crossover between the two scFvs would
produce a plasmid without a chimeric gene. (D) Homologous recombination when scFv 1
has 3' homology to the display vector and scFv 2 is not present. This recombination
occurs between the (gly4ser)3 linker that joins the scFv heavy and light chains and the
(gly4ser)3 linker located immediately 5' to the ultimate location of the gene in the display
plasmid.
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Nucleotide # 0 60 120 180 300 360 420 480 540 600 660 720 780
scFvl 
scFv2
clone# #of
clones
A. 1 30 I I I II
2 63 1 '.li . . I I 
4 1 ii " I I I
5 1
6 3
7 1 _
8 1 ___
9 2 .
10 1
11 1 __ _ '.
B.
C
D
12 23
13 6
14 1
15 1
16 1
17 1
18 5
19 1
20 2
21 1
22 1
23 1
24 1
25 1
26 23
27 14
28 1
29 1
30 1
31 1
32 1
33 2
34 2
35 10
36 2
Figure 2.4: Results of homologous recombination shuffling experiments. scFv I is
shown in blue, scFv 2 is shown in red, and the differences between them are indicated by
black bars connecting the two. (A) Chimeric clones produced by homologous
recombination of scFv 1 with 3' homology to the cut vector and scFv 2 with 5' homology
to the cut vector. (B) Chimeric clones produced by homologous recombination of scFv 1
with 5' homology to the cut vector and scFv 2 with 3' homology to the cut vector. (C)
Clones produced when both scFv 1 and scFv 2 have 5' and 3' homology to the cut vector.
(D) Clones produced when only scFv 1 with 3' homology to the cut vector is
transformed.
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Chapter 3: Integrated Mimicry of B Cell
Antibody Mutagenesis
by PCR and Homologous
Recombination in Yeast
3.1 Introduction
B cells utilize a variety of mechanisms to adaptively generate antibody sequence
diversity. Preimmune V(D)J recombination first creates CDR3 loops of varying length
and composition53 . Then, in response to antigen challenge, the antibody repertoire is
further shaped by somatic hypermutation (SHM)54, combinatorial replacement of entire
light chains (receptor editing6 '8), and exchange of portions of the VH gene (receptor
revision9 , 10). Light chain exchange in the periphery has been observed in humans7 and
mice8, and has been proposed to play a role in fine tuning antigen binding affinity55.
Receptor revision creates hybrid VH genes that maintain the same CDR3 while splicing in
new coding sequence for FRi, CDRl, FR2, CDR2, and most or all of FR356' 57 Receptor
revision and receptor editing cause larger movements in sequence space than SHM, and
are hypothesized to enable the affinity maturation process to escape local energetic
minima58. Amino acid insertions and deletions in CDRs occur frequently in vivo3 5, and
such changes are well tolerated by the variable region's framework architecture 59. The
broad spectrum of mutational strategies employed by B cells ensures a thorough search of
sequence space surrounding the critical VH CDR3 residues that dominate antigen
recognition in the preimmune repertoire6 0 ' 61
In contrast, in vitro antibody affinity maturation strategies to date have employed
mutagenesis with a much narrower scope. Diverse antibody libraries for affinity
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maturation have been generated by random mutagenesis throughout the entire variable
regions30 31 62, gene shuffling 31 , targeted mutagenesis of CDR residues63 64, light chain
shuffling4 2' 65, and CDR shuffling42' 65, 66. Most in vitro antibody affinity maturation
strategies employ error-prone PCR for mutagenesis, which can sample a varying
frequency of nucleotide point mutations3 0. Random mutagenesis in conjunction with
gene shuffling3 ' and targeted mutagenesis of CDR residues63 have shown to yield
dramatic affinity improvements of 3 orders of magnitude or greater. Methods that
involve chain or CDR shuffling have proven less successful, with affinity improvements
up to 300 fold when directed against a hapten antigen42 and up to 6 fold when directed
against a protein antigen65' 66. The mutagenesis methods just enumerated have been used
previously in isolation, or in pairs. However, for a given antibody/antigen pair it is not
possible to identify a priori the particular categories of genetic diversity from which the
greatest affinity improvements will be isolated.
In this study, we have developed an integrated approach combining error prone
PCR and in vivo homologous recombination in yeast that mimics the full spectrum of
mutagenesis strategies employed by B cells: random point mutagenesis, amino acid
insertions and deletions, receptor revision, and receptor editing. This approach has been
applied to increase the affinity of an anti-peptide antibody by at least five orders of
magnitude, from uM to pM affinity, in three library construction and screening steps.
Facile access to sequence diversity beyond point nucleotide mutations mimics the
approach used by the humoral immune system to ensure a robust adaptive response
against effectively any macromolecular antigen presented on a pathogenic surface. In
addition, this multiplexing affinity maturation strategy decreases the likelihood of
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convergence upon a single high affinity solution, allowing for the generation of multiple
high affinity binders, with potentially different secretory properties and therapeutic
potential.
3.2 Materials and Methods
3.2.1 Materials
The non-immune library used to isolate anti-PSGL- binders has been previously
described5°. The divalent, biotinylated b.19.ek.Fc (a biotinylated bivalent fusion of the
N-terminal 19 amino acids of PSGL-1 to a human Fc) protein and the human Fc were
generous gifts of Dr. Raymond T. Camphausen, formerly of Wyeth (Cambridge, MA)2 4 .
The monovalent from of this antigen lacking the Fc portion, b.19.ek, was a gift of Gray
Shaw (Wyeth, Cambridge, MA). The yeast strain used for all experiments, EBYIOO, has
been previously described16 . The yeast surface display vector PCTCON, a derivative of
the vector PCT302, has also been previously described50 .
All restriction enzymes and ligases were purchased from New England Biolabs
(Beverly, MA). Mouse monoclonal antibody, 9e10, directed against the c-myc epitope
tag, was purchased from Covance (Richmond, CA). The fluorophores goat anti-mouse
FITC, goat anti-biotin FITC, and goat anti-mouse PE were purchased from Sigma (St.
Louis, MO) and streptavidin-PE was purchased from PharMingen (San Diego, CA).
3.2.2 Mutagenic PCR
Mutagenic PCR of the anti-PSGL-1 scFv was performed using the nucleotide
analogues 8-oxo-2'-deoxyguanosine-5'-triphosphate (8-oxodGTP) and 2-deoxy-P-
nucleoside-5'triphosphate (dPTP), which were both purchased from TriLink
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Biotechnologies (San Diego, CA)4 0 67. Primers were ordered from MWG Biotech (High
Point, NC). The forward primer was 5'-
CGACGATTGAAGGTAGATACCCATACGACGTTCCAGACTACGCTCTGCAG-3'
and reverse primer was 5'-
CAGATCTCGAGCTATTACAAGTCTTCTTCAGAAATAAGCTTTTGTTC-3'. These
primers have approximately a 50 basepair overlap with PCTCON that has been digested
from NheI to BamHI. PCR reactions were carried out on a Perkin Elmer DNA Thermal
Cycler 480. All mutagenic PCR reactions were carried out in a 100 uL volume using 10-
100 ng of template, 1 uM primers, 0.2 mM of each dNTP, 6.25 U Taq (Invitrogen,
Carlsbad, CA), and 2 mM MgCI2. To vary the mutation rate, both the concentration of
the analogues and the number of PCR cycles was varied. Six separate PCRs were
performed: 5 cycles with 200 uM analogues, 10 cycles with 200 uM analogues, 10
cycles with 20 uM analogues, 10 cycles with 2 pM analogues, 20 cycles with 20 uM
analogues, and 20 cycles with 2 uM analogues. The cycling conditions used were 1 cycle
of 940C for I minute followed by either 5, 10 or 20 cycles of 940C for 1 minute, 500C for
I minute, 72°C for 2 minutes, followed by I cycle of 720C for 10 minutes. PCR products
were gel purified using a Qiagen (Valencia, CA) kit. After purification, a 1:50 dilution of
the 20 cycle purified PCR product and a 1:10 dilution of the 10 cycle PCR product were
prepared and 5 uLs were used in a 100 uL PCR reaction with the following cycling
conditions: 1 cycle of 940C for 1 minute followed by 30 cycles of 940 C for 1 minute,
500C for I minute, 720C for 2 minutes, followed by 1 cycle of 720C for 10 minutes. For
the 5 cycle PCR purified product, the PCR was performed in the same way except the
purified template was not diluted. All amplifications were performed using the same
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concentrations of reagents as in the mutagenic PCR except the nucleotide analogies were
omitted. The PCR amplified products were gel purified using a Qiagen kit.
3.2.3 Receptor Revision and Receptor Editing Libraries of Anti-PSGL-1 scFvs.
The libraries where the VH CDRs were preferentially replaced were created from
truncated PCR products based upon r2s4-2. Library RRI was created by cotransforming
a r2s4-2 PCR product that lacked the first framework region and CDR of the VH with a
pool of PCR products generated from non-immune library DNA. Library RR2 was
created in a similar manner except the r2s4-2 PCR product lacked the first two CDRs and
first two framework regions. The fact that the PCTCON vector contains a BamHI cut site
5' to the c-myc tag and a XhoI site 3' to the c-myc tag was used to facilitate library
construction. To force recombination, it was necessary to restrict 5' homology to the cut
vector to the pool of non-iummune library PCR products and to restrict 3' homology to
the cut vector to the r2s4-2 PCR products. The forward primer HA-for, 5'-
GTTCCAGACTACGCTCTGCAG-3', which primes in the HA region of PCTCON and
is well 5' of the NheI cut site that begins every scFv, was used to generate non-immune
library PCR products for the RR1 and RR2 libraries. The reverse primer used to generate
non-immune library based PCR products, c-myc-library-rev, 5'-
CTTCTTCAGAAATAAGCTTTTGTTC-3', primes in the c-myc region and creates
fragments that lack 3' homology to an NheI to XhoI digested PCTCON backbone. For
library RRl, r2s4-2 based PCR products were created using the forward primer FR2-for,
5'-GGATCAGGCAGTCCCCATCG-3', which primes in framework 2 and for library
RR2, r2s4-2 based PCR products were created using the forward primer FR3-for,
5'CGAATAACCATCAACGCAGAC-3', which primes in framework 3. The reverse
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primer in both cases was past-XhoI-rev, 5'-GGGAACAAAGTCGATTTTGTTAC-3'
which primers 3' to the XhoI site. The cutting of the backbone PCTCON from Nhel to
XhoI ensured that the non-immune library fragment would insert on its 5' end and the
r2s4-2 fragment would insert on its 3' end because neither fragment alone would have the
necessary homology to form a complete plasmid.
The receptor editing library was created in a slightly different manner. The
PCTCON backbone was digested from NheI to BamHI. A VH only fragment of r2s4-2
was generated using the HA-for primer and a reverse primer VL-rev, 5'-
GGAGACTGTGTCAACACAATTTC-3', that primes 3' to the (gly4ser)3 linker. The
non-immune library DNA was PCRed using the HA-for primer and a reverse primer c-
myc-rev, 5'-CAGATCTCGAGCTATTACAAGTCTTCTTCAG-3'. The non-immune
library PCR products for the creation of a receptor editing library were digested from
Nhel to BamHI to eliminate the 5' homology to the cut PCTCON. There is a conserved
BamHl site in most scFvs 5' to the (gly4ser)3 linker thus cutting with BamHI generated a
pool of light chain fragments.
All PCR reactions were carried out in a 100 /L volume using 10-100 ng of
template, 1 pM primers, and 0.2 mM of each dNTP. For the amplification of fragments
based upon r2s4-2, 2.5 U of PfuTurbo (Stratagene, La Jolla, CA) were used to decrease
the likelihood of introducing mutations. For amplification of non-immune library DNA,
6.25 U of Taq and 2 mM MgCl 2 were used. The cycling conditions were 1 cycle of 94°C
for 3 minutes followed by 35 cycles of 940C for minute, 550 C for 1 minute, 720 C for
1.5 minutes, followed by 1 cycle of 720C for 10 minutes. All PCR fragments were
purified using a Qiagen PCR purification kit
45
3.2.4 Yeast Transformation
Insert fragments were concentrated with Pellet Paint (Novagen, Madison, WI) to a
concentration of 5 ug/ul according to the manufacturer's instructions and cut PCTCON
backbone was likewise concentrated to a concentration of 1 ug/l. The insert to
backbone ratio was 10:1 on a mass basis. For the receptor revision and receptor editing
libraries the insert was an equal mix of non-immune library PCR product and r2s4-2 PCR
product. The method for the preparation of electrocompotent yeast and their
transformation has been described previously6 8 . Transformation efficiencies were on the
order of 105 transformants per microgram of insert DNA.
3.2.5 Yeast Growth and Induction
Detailed protocols for yeast growth and induction can be found in Boder and
Wittrup, 200069.
3.2.6 Flow Cytometry for Sorting and Kd Determination on the Yeast Surface
All sorting was performed on a MoFlo cell sorter (Cytomation, Fort Collins, CO).
For the lead isolation round of anti-PSGL-1 scFvs, a subset of 2.3 * 108 clones from a
library with overall diversity of I * 109 clones50 was sorted for potential binders. Three
total sorts were performed at a concentration of 800 nM b.19.ek.Fc and, to prevent
isolating fluorophore binders, goat anti-biotin FITC and streptavidin-PE were alternately
used to detect b.19.ek.Fc binding clones. In addition, 10 fold excess human Fc was
added as a competitor in the second and third sorts to prevent isolation of Fc binders.
The DNA of all sixteen clones isolated from round 0 were pooled and mutagenized
together. This new pool of mutant DNA was transformed into yeast and plasmids were
recreated using in vivo homologous recombination44 to create a round library of 4.8*106
clones. The library was sorted six times at a concentration of 100 nM b. 19.ek.Fc for sorts
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1-4, 50 nM b.19.ek.Fc for sort 5, and 25 nM b.19.ek.Fc for sort 6. For round 2, a library
of 1.8 * 107 was created by in vivo homologous recombination and sorted four times
using 50 nM b. 19.ek.Fc for sort 1, 25 nM b.19.ek.Fc for sort 2, 10 nM b.19.ek.Fc for sort
3, and 5 nM b.19.ek.Fc for sort 4. For round 3, the random mutagenic library contained
2.3 *107 clones and was 13.5 times larger than the receptor editing library and 77 fold
larger than two receptor revision libraries. All four of these libraries were sorted four
times separately using a concentration of 5 nM divalent b.lO.ek.Fc for the first sort, 5 nM
b.19.ek.Fc plus 33 fold excess KPLI for the second sort, 5 nM monovalent b.19.ek for
the third sort, and a concentration of 2.5 nM b. 19.ek for the fourth sort.
Between sort analysis and titrations for determining scFv Kds were performed on
a Coulter EPICS XL (Miami, F). For analysis, approximately 2 * 106 yeast were
suspended in 100 ul of PBS + 0.1% BSA (to be referred to as PBS in this paper). Cells
were labeled with either b. 19.ek.Fc or b. 19.ek at the appropriate concentration for /2 hour
at 37C. After a wash with 1 mL of cold PBS, the yeast were incubated 2 hour on ice
with 9e 10 in a 1:100 dilution in PBS. After a cold PBS wash, the yeast were incubated 1/2
hour on ice with either goat anti-mouse FITC in a 1:50 dilution plus streptavidin-PE in a
1:100 dilution in PBS or goat anti-mouse PE in a 1:25 dilution and goat anti-biotin FITC
in a 1:50 dilution in PBS. For sorting, these labeling conditions were scaled
appropriately for the increased number of yeast. The method for the determination of
optimum labeling concentrations and sort windows has been shown earlier69 . The
method for performing a titration to determine the Kd of yeast surface displayed scFvs has
also been described previously6 9 .
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3.2.7 Representation of the Electrostatic Potential at the Surface of Clone
RR2r3s4-1
The model of the antibody RR2r3s4-1 was created using the website Web
Antibody Modeling (antibody.bath.uk.ac.uk). The solvation potential at the surface was
computed by solving the Poisson-Boltzmann equation (inner dialectric constant = 4, outer
dialectric constant = 80) using an in-house modified version of the program DELPHI
(Tidor Group, Massachusetts Institute of Technology, Cambridge, MA). It was modeled
using CHARMM19. Special thanks to Michael D. Altman for the software used to plot
the electrostatic potential at the surface.
3.3 Results
3.3.1 Lead Isolation Round 0
A previously described5 0 nonimmune antibody displayed on the surface of yeast
was sorted for binders to a biotinylated bivalent fusion of the N-terminal 19 amino acids
of PSGL- I1 to a human Fc (b. 19.ek.Fc)24 . This construct contains the portion of PSGL-1
that has been determined to be both necessary and sufficient for adhesion to P-selectin2 4
and is an important drug target for the development of anti-inflammatory therapeutics7 0
(Figure 3.1). After three sorts, a sample of sixteen clones was sequenced and all were
found to be unique (data not shown). The pool of clones was verified to be specific for
b. 19.ek.Fc because the pool did not show decreased binding in the presence of ten fold
excess Fc and did not bind fluorophores in the absence of b.19.ek.Fc. The bivariate
histogram showing the binding of the best clone from this round can be seen in Figure
3.2A. The Kd values for clones isolated in this round are difficult to determine because of
lack of sufficient b. 19.ek.Fc to create the necessary concentrations needed to measure the
Kd; additionally, at concentrations greater than 1 pM nonspecific ligand stickiness to the
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yeast's surface becomes problematic. However, a lower bound Kd estimate of greater
than 5 uM (Figure 3.3) was made from an examination of binding data at concentrations
below saturation (data not shown). The CDR amino acid sequence of two of the clones
from this round, rOs3-6 and rOs3-15, are shown in Table 3.1. The best binding clone from
this round was not rOs3-6 or rOs3-15, the two clones that provided genetic material for the
subsequent affinity maturation rounds.
3.3.2 Affinity Maturation Round 1 Utilizing Random Mutagensis and Receptor
Editing
After six sorts, a single clone, termed rls6-15, was isolated from a library made of
pooled DNA from round 0 that had been mutagenized and transformed together. This
clone displayed much better than the best clone from the previous round (Figure 3.2A
and 3.2B). Surprisingly, this clone was not entirely derived from any single clone from
the lead isolation round but was a hybrid with a VH that had a 99.5% match to the rOs3-6
VH and a VL that had a 100% match to rOs3-15 VL (Table 3.1 and Figure 3.3) indicating
that receptor editing had occurred through in vivo homologous recombination within the
(gly4ser)3 linker region shared by all scFvs. The only mutation was glutamic acid to
glycine in VHCDR3.
Again, an accurate Kd of clone rl s6-15 was not determined, however an estimate
of a Kd of between 1 and 5 uM (Figure 3.3) was made from an examination of binding
data at concentrations below saturation (data not shown). Specificity for the N-terminal
19 amino acids of PSGL-1 was verified by observing the absence of b. 19.ek.Fc binding
to rls6-15 displayed on the surface of yeast in the presence of a 10 fold excess of the
commercially available anti-PSGL-1 antibody KPL1 which has been shown to bind the
desired epitope 71 (Figure 3.4A and 3.4B). In addition, rls6-15 did not show reduced
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binding to b. 19.ek.Fc in the presence of a 10 fold excess of an anti-enterokinase binding
monoclonal antibody (Figure 3.4A and 3.4C) or a 30 fold excess of a human Fc (Figures
3.4D and 3.4E).
3.3.3 Affinity Maturation Round 2 Utilizing Random Mutagensis
The best clone from round 1 was subject to random mutagenesis throughout the
entire gene. Ultimately, one clone was isolated with three mutations, one in the linker
region, one in the VHCDR3, and one in the VLCDR3 (Table 3.1). For this clone, both the
monovalent affinity, 50 ± 30 nM, and divalent affinity, 90 110 pM, were determined
(Figure 3.3). This data allows for the affinity improvement due to avidity to be estimated
using the theory of Jencks72. The essence of this theory is that the Kd for the binding of
two tethered binding sites A and B, KdAB, is not equal to the product of the Kd for the
binding of A to its ligand, KdA, times the Kd for the binding of B to its ligand, KdB:
KdAB K AKd B 3.1
Equation 3.1 cannot be valid because the units are equal to concentration on the left side
of the equation and concentration squared on the right side of the equation. It is possible
to define a unitless Kd, K,, that makes Equation 3.1 valid:
KdAs = KdA Ku 3.2
This unitless Kd is defined as
B
KB Kd 3.3
[A/B],el
where [A/B]eff is the effective concentration of B given that A has already bound.
Substituting equation 3.3 into 3.2 we get
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KdAB Kd3.4K[AIB]e 
The protein b. 19.ek.Fc has two identical binding sites so
Kd = Kd 3.5
[A/B]eff= [A/A]ff 3.6
KdAB = KdAA 3.7
Therefore, substituting equations 3.5, 3.6, and 3.7 into 3.4 we get
K d K 3.8[A / A]eff
The Kd for divalent binding, KdAA, will be enhanced by the increased local concentration
of A due to avidity when one A is already bound as long as KdA is less than [A/A]ejj. When
KdA = [A/A]; the divalent KdAA is equal to the monovalent KdA and there is no avidity
effect. Using the data from round 2 the effective concentration of PSGL- I1 that is tethered
to already bound PSGL-1 is equal to 28 /uM. The display level on the yeast surface
affects the local environment and therefore affects the effective concentration. Because
the round 0 clones are less well displayed than those in subsequent rounds (Figure 3.2),
the effective concentration in round 0 is likely to be less than 28 /uM. However, using an
effective concentration of 28 uM gives an estimate of the lower bound of the monovalent
Kd in round 0. Substituting the divalent Kds for round 0 and 1 and the effective
concentration of 28 uM into the Jencks equation, the monovalent Kd for round 0 and 1
can be estimated to be in the low micromolar range (Figure 3.3).
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3.3.4 Affinity Maturation Round 3 Utilizing Random Mutagensis, Receptor
Revision, and Receptor Editing
To compare receptor revision, receptor editing, and error-prone PCR random
mutagenesis, four separate libraries were created, all based upon r2s4-2. The random
mutagenic library was 13.5 times larger than the receptor editing library (Figure 3.5C)
and 77 fold larger than two receptor revision libraries (Figure 3.5A and 3.5B). Two
different receptor revision libraries were made using in vivo homologous recombination,
one (RR1) that biased crossovers to the FR2 region leading to a preferential replacement
of r2s4-2's VHFR1 and VHCDRl (Figure 3.5A) and one (RR2) that biased crossovers to
the FR3 region leading to preferential replacement of r2s4-2's VHFR1, VHCDRI, VHFR2,
and VHCDR2 (Figure 3.5B). The receptor editing library, RE, was made to replace only
the light chain with new light chains from the nonimmune library (Figure 3.5C). In all of
these libraries, VHCDR3 was maintained because previous studies have indicated that this
domain is in the center of the antigen binding site and is often significant in determining
antibody specificity6 0 61. Our strategy was to alter regions in the binding site periphery
such as the VHCDR1, both the VHCDRI and VHCDR2, and the light chain in order to
further optimize the binding site. This approach is analogous to the genetic diversity
mapped onto antibody binding sites following somatic hypermutation and affinity
maturation in vivo61 . Diversity in these libraries is generated from nonimmune library
DNA which codes for sequences already selected as being both compatible with the
antibody fold and presumably functionally expressed in vivo.
Table 3.2A shows that for a random sampling of ten clones from the RRI library
six had a new CDR1 but maintained the original VHCDR2 and VHCDR3, indicating that
the crossover occurred in FR2 as designed. Two clones had new heavy chains but were
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from the same VH6-1 germline gene as the VH in r2s4-2. One clone had a new heavy
chain altogether. From this data, it appears that roughly half of the hybrid genes created
had a crossover in FR2. Table 3.2B indicates that for a random sampling of ten clones
from the RR2 library, four had a crossover in FR3 leading to clones with a new VHCDR1
and VHCDR2 but maintained the VHCDR3. Four clones had new heavy chains and two
clones not shown in the table were VL only. Light chain only clones were generated by a
crossover between the (gly4ser)3 linker 5' to the light chain and the (gly4ser) 3 linker in
the display plasmid 5' to the region coding an scFv. Thus, roughly half of the clones in
RR2 had new sequences 5' to the r2s4-2 VHCDR3.
Table 3.2C shows that four of ten clones sampled from the receptor editing library
had new light chains. Three had new K chains and one new chain was a A chain. Six of
the clones contained only a light chain or a duplicate of the r2s4-2 heavy chain and a new
light chain. In a similar manner to light chain only clone formation, clones with duplicate
r2s4-2 VHS were generated by a crossover of a VH with the (gly4ser)3 linker of a second
VH which then crosses over with the (gly4ser)3 linker 5' to the VL. Again, roughly half
of the clones had a single VH and a new VL.
All of the libraries except the RE library yielded affinity improvements over r2s4-
2 (Figure 3.2F-J). The mutagenic library best clone, called r3s4-3, had a Kd for
monovalent b.19.ek of 180 ± 100 pM, the RR1 library best clone, called RRlr3s4-2, had
a Kd for b. 19.ek of 220 ± 200 pM, and the RR2 library best clone, called RR2r3s4- 1, had
a Kd for b. 19.ek of 70 ± 60 pM (Figure 3.3). The total monovalent affinity improvement
after three rounds of mutagenesis is estimated to be at least five orders of magnitude.
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Sequencing revealed three mutations in the mutagenic library best clone, one in
VHCDR2, one in VHCDR3, and one in VLCDR2 (Table 3.1). The RR1 library best clone
had three mutations in VHCDR1 and an insertion of an arginine into VHCDR2 (Table
3.1). The RR2 library best clone also had three mutations in VHCDR1, although only two
were different than the three found in the VHCDR1 of the best clone from RRI, the same
arginine insertion found in the best clone from RR1, and three additional mutations in
VHCDR2 (Table 3.1). The discovery of an arginine insertion in VHCDR2 is a result of
the receptor revision method and would not be found through error-prone PCR
mutagenesis. The ability to easily isolate beneficial insertions and deletions is an
important advantage of the receptor revision method.
3.3.5 Framework Mutations in Isolated Clones
It is important to know how many mutations the framework regions of each scFv
have because it is common belief in industry that antibodies with framework mutations
are more likely to be immunogenic than those that do not contain framework mutations.
The sequence of each scFv is compared to the framework sequences in Appendix A. The
clone rls6-15 has five framework mutations, three in the heavy chain and two in the light
chain. These same two light chain framework mutations appear in all subsequent clones.
Moreover, clones r2s4-2 and r3s4-3 have the same heavy chain framework mutations as
in rls6-15. Clone RRlr3s4-2 has the same mutations as in the rls6-15 heavy chain
framework regions plus one more mutation in VHFR1. Clone RR2r3s4-1 also has four
total mutations in the heavy chain framework regions but only one is the same as in clone
RRI r3s4-2.
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It was not determined whether or not any of the framework mutations were
essential to the affinity of a given clone. If necessary, site directed mutagenesis could be
used to change each framework mutation back to the amino acid present in the germ line.
3.3.6 Electrostatic Potential at the Surface of Clone RR2r3s4-1
The electrostatic potential at the surface of clone RR2r3s4-1 is shown in Figure
3.6. This figure is based upon a hypothetical model and is not an actual crystal structure.
Therefore, the orientation of the residues may not be exact and the residues may have a
different orientation when bound to PSGL-1. However, the model proves useful in
demonstrating the charge distribution in the binding site. It is immediately apparent that
the binding site of the antibody is very blue in comparison with the rest of the antibody,
indicating that this region is of positive electrostatic potential. Since this antibody binds
to a peptide that contains negatively charged sulfotyrosines it makes sense that the
antibody binding site would be positively charged. A number of arginines, including
Arg3 1, Arg94, Arg162, Arg166, Arg167, and Arg216 are within the hypothetical binding
site. Arg94 was introduced in round 2 of the affinity maturation and Arg167 was an
arginine insertion in round 3 of the affinity maturation. Arg31 is a mutation from the
germline sequence that was within one of the two starting antibodies isolated in the lead
isolation round. Arg162 and Arg166 are both residues that are within the germline
sequence that contribute to the positive electrostatic potential in the binding site. In
addition, Arg216, which is within VHCDR3 and is not a mutation caused by the affinity
maturation process, also contributes to the positive electrostatic potential. It is interesting
to point out that two histidines were added during the affinity maturation and appear at
the center of the binding site. His218 was introduced in round 2 of the affinity
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maturation and His147 was introduced in round 3. His33 is a mutation from germline
and is also within the binding site. Histidines may or may not be protonated at
physiological pH depending on the local environment. Thus, it is possible that the
histidine mutations may further contribute to positive charge within the binding site. One
negatively charged group, Glu213, was mutated to Gly213 in round 1 of the affinity
maturation thereby removing a negatively charged residue from the biding site. It
appears that optimization of charge within the antigen binding site was vital for the
affinity maturation of this antibody.
3.5 Discussion
Receptor revision and receptor editing (recombinatorial mutagenesis) both have
been shown to occur during affinity maturation in human germinal centers9 ' " 73. B cell
immunoglobulin gene rearrangements in the periphery have been theoretically described
as a way to allow antibodies to make large leaps in sequence space in order to escape
local optima on the affinity landscape5 8. This additional process of receptor
diversification is believed to have an advantage over affinity driven selection based upon
point mutations alone because point mutations allow for an antibody to affinity mature
only toward a local optimum (Figure 3.7). Because the antibody must pass through lower
affinity intermediates, which are lost during affinity driven selection, to reach other
optima, the antibody cannot move to other regions of the affinity landscape that
potentially contain optima of higher affinity. The immune system appears to exploit
recombinatorial mutagenesis to swap in larger functional portions of the variable
antibody domain, generating binding motifs with substantially altered structure and
higher affinity than can be obtained by point mutation alone.
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The previous explanation provides a theoretical basis for recombinatorial
mutagenesis to exist in vivo. This logic can be extended to provide a basis for using
recombinatorial mutagenesis as a strategy for creating antibody libraries in vitro. For
example, the benefits of using recombinatorial mutagenesis in addition to point
mutagenesis becomes clear when one considers the median fitness of a population and
the frequency distribution of fitness in a population generated by each method7 4. A
library generated by point mutagenesis of a given antibody will have a slightly lower
median fitness than the fitness of the starting antibody. In addition, the fitness distribution
will be narrow. A library generated by using recombinatorial mutagensis of a given
antibody will exhibit a much lower median fitness than a point mutagenesis generated
library but will have a much larger fitness distribution. As a result, most clones in the
library will exhibit much lower fitness than the starting point but the large variance
increases the likelihood that the best clones in a recombinatorial mutagenesis library will
exhibit higher fitness than the best clones in the point mutagenesis library.
However, in vitro methods of generating library diversity other than point
mutagenesis have not yielded remarkable results. First, there is no facile method for
making libraries with amino acid insertions and deletions because the residues that need
to be added to or removed are not readily apparent. Methods based upon receptor editing
or receptor revision have been used but still have not been successful enough to become
common practice. Large scale replacement of whole regions of scFv DNA were
successful in engineering a binder against a hapten with an affinity improvement of 2
orders of magnitude42 but had little success against a protein antigen65. Furthermore, in a
study by Ellemark et al., swapping of the VHCDR2 and light chain did not yield anti-
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protein antibodies with higher Kd values but did produce antibodies with faster on rates66 .
What becomes clear is that the success of a given mutagenesis tactic is an unpredictable
consequence of the specific antibody lineage and antigen - thus, the capability to rapidly
explore multiple mutagenic mechanisms raises the probability of generating a
functionally improved mutant antibody.
In this paper, we have successfully employed an integrated approach utilizing
both random mutagenesis and recombinational mutagenesis to affinity mature an anti-
peptide scFv at least five orders of magnitude. This approach incorporated random
mutagenesis in each round of affinity maturation but also included beneficial receptor
editing in round 1 and receptor revision plus amino acid insertion in round 3. In round 3,
where receptor revision and random mutagenesis were compared head to head, each
method generated equivalent affinity improvements although the recombinatorial
mutagenesis library was 77 fold smaller than the random mutagenesis library. However,
this result does refute the hypothesis that recombinatorial mutagenesis allows for greater
improvements in affinity than point mutagenesis. First, the libraries compared were not
of equal size. Second, it is possible that several local optima on the affinity landscape
correspond to roughly equivalent affinities. Therefore, it is possible that the local
optimum that the antibody reached by random point mutagenesis in round 3 was of the
same affinity as the local optimum in a different place on the affinity landscape that the
antibody was able to find through recombinatorial mutagenesis. In addition, although not
applicable to the case considered in this paper, it is important to mention that if an
antibody is at an affinity near the global optimum, recombinatorial mutagenesis can only
lead to reduced fitness. Likewise, if an antibody is at its local optimum, recombinatorial
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mutagenesis is the only method that can lead to increased fitness. Therefore, the success
of a given method is highly dependent on the location of a given antibody on the affinity
landscape. In order to fully compare the two methods, several antibodies must be affinity
matured against different antigens using libraries of equivalent size.
The results of this paper, however, do validate recombinatorial mutagenesis as a
mutational strategy and demonstrate at which step in the affinity maturation process
receptor editing and receptor revision may be beneficial. There is evidence that receptor
editing is more likely to be beneficial when the affinity for the antigen is low, probably in
the hundreds of nanomolar range or weaker. This observation is in agreement with
Marks et al. in which an anti-hapten antibody (Kd = 320 nM) was first affinity improved
by shuffling the light chain and then further improved in a receptor revision like event
yielding a total of 2 orders of magnitude affinity improvement4 2. When receptor editing
and receptor revision were performed separately on an antibody that already had a 16 nM
affinity for a protein antigen, improvements achieved by each method were not
additive6 5. As Tomlinson et al. demonstrated, diversity in the antibody primary
repertoire is confined to the CDR3 of each chain and spreads outward to the periphery of
the binding site during somatic hypermutation6 1. It may be that in a similar manner
receptor revision makes changes in the VHCDRI and VHCDR2, which are part of the
binding site periphery, to allow for affinity improvements after some threshold affinity
has been reached which is determined by the CDR3s of the heavy and light chains. This
explanation is consistent with our observation that receptor editing was beneficial in
round 1 when the affinity of the parental pool was low but did not yield an affinity
improvement in round 3 when the parental antibody already had nanomolar affinity.
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Receptor revision, however, was able to generate a two orders of magnitude affinity
improvement in round 3 despite the relatively high affinity of the parental antibody.
Moreover, a facile method for recombinatorial mutagenesis that is not possible
using display technologies other than yeast is demonstrated. The high fidelity method of
in vivo homologous recombination in yeast allows for the creation of hybrid genes
between a known sequence and nonimmune library DNA without PCR assembly,
ligation, and cloning. Thus, recombinatorial mutagenesis is as easy to use as random
mutagenesis. Furthermore, it is the only known method that allows for easy access to
beneficial amino acid insertions and deletions that have been retained in the starting non-
immune antibody repertoire.
Our results suggest that it is best to incorporate multiple mutagenic strategies in
the affinity maturation. Chain shuffling should be used in the early rounds of the affinity
maturation but not when the affinity has improved to the nanomolar range. Although in
the case shown here, recombinatorial mutagensis lead to an affinity improvement equal to
that obtained through random mutagensis, recombinatorial mutagenesis, because it allows
for the possibility of significant structural change, has the advantage of potentially
creating antibodies that may have reduced framework divergence, different cross
reactivity, and different therapeutic potential. The strategy presented here is uniquely
capable of straightforwardly mimicking the genetic spectrum generated by B cells during
affinity maturation in vivo. Our integrated approach, made possible by the in vivo
homologous recombination mechanism in yeast, should prove a valuable tool for
antibody engineering.
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Table 3.1: Amino acid sequences of the CDRs of the best clones isolated in each round
of affinity maturation for anti-PSGL- 1 antibodies.
A. Round 0
Clone Name VHCDR1 VHCDR2 VHCDR3 VLCDR1 VLCDR2 VLCDR3 Other Mutations
rOs3-6 SNNVAWN RTYYRSKWYNDYAASVKS EGGRAQSA RASQRVSTTYLA AASRRAT QHYRSSPPLT
rOs3-15 SYYWT YIHNSGSTNYNPSLKS RLKSGWFAGWFGP RASQSVSRSHLA GASSRAT QQYGSPGVT
B. Round 1
Clone Name VHCDR1 VHCDR2 VHCDR3 VLCDR1 VLCDR2 VCDR3 Other Mutations
rl s6-15 SNNVAWN RTYYRSKWYNDYAASVKS GGGRAQSA RASQSVSRSHLA GASSRAT QQYGSPGVT
C. Round 2
Clone Name VHCDR1 VHCDR2 VHCDR3 VLCDR1 VLCDR2 ViCDR3 Other Mutations
r2s4-2 SNNVAWN RTYYRSKWYNDYAASVKS GGGRAHSA RASQSVSRSHLA GASSRAT QQYGRPGVT Linker G to R
D. Round 3
Clone Name VHCDR1 VHCDR2 VHCDR3 VLCDR1 VLCDR2 VLCDR3 Other Mutations
SNNVAWN RTYYRSKWYNDYAASVKG
SNTAAWN RTYYRRSKWYNDYAASVKS
GGSRAHSA
GGGRAHSA
RR2r3s4-1 SNAAWH RTYYRRSKWNYDYALSVKS GGGRAHSA
RASQSVSRSHLA GVSSRAT QQYGRPGVT
RASQSVSRSHLA GASSRAT QQYGRPGVT VHFR1 Q to H
VHFR1 V to I
RASQSVSRSHLA GASSRAT QQYGRPGVT VHFR3 T to N
VHFR3 A to P
VHFR3 Q to L
VHFR3 H to Q
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r3s4-3
RR1 r3s4-2
Table 3.2: CDR amino acid sequences for a random sampling of clones from round 3
receptor revision and receptor editing libraries directed against PSGL-1
prior to sorting.
A. Round 3: Receptor Revision with VHFR1 + VHCDR1 Preferentially Exchanged
VHCDR1
SNNVAWN
SNSAAWN
SNSATWN
SNNVAWN
GNSATWN
TNNTAWN
SNAAGWN
RFAVS
VHCDR2
RTYYRSKWYNDYAASVKS
RTYYRSKWYNDYAASVKS
RTYYRSKWYN DYAASVKS
RTYYRSKWYNDYAASVKS
RTYYRSKWYNDYAASVKS
RTYYRSKWYNDSAVSMKS
RTYYRSKWSTDYAVSVKG
VIPMFGTPKYAQRFQG
VHCDR3
GGGRAHSA
GGGRAHSA
GGGRAHSA
GGGRAHSA
GGGRAHSA
DGGLGPQR
ARWGGLERRLYHFDF
DAARGYGSGIEAFDI
B. Round 3: Receptor Revision with VHFR1, VHCDR1, VHFR2, VHCDR2 Preferentially Exchanged
VHCDR1
SNNVAWN
SNTAAWN
SNTAAWN
HDGAAWN
SNTAAWN
NTDAAWH
SN SAAWN
SNSAIWN
DYAMH
VHCDR2
RTYYRSKWYNDYAASVKS
RTCYRSKWYFDYAPSVKS
RTYYRSKWYNDYAVSVKS
RTYYRSKWYYGYAISVKS
RTYYRSKWYSDYAVSLKS
RTNFRSKWSNDYALFVKS
RTHYRFKWYSDYAVSVKS
RTYYRS QWYN DYAVSVKS
GISWNSGSIAYADSVKG
VHCDR3
GGGRAHSA
GGGRAHSA
GGGRAHSA
GGGRAHSA
GGGRAHSA
QYGWNLGH
GSKSSFDY
DLAGFDY
DIRGYYDSSGGFDP
C. Round 3: Receptor Editingt
# of Chain
clones VLCDR1 VLCDR2 VLCDR3 Name
original RASQSVSRSHLA GASSRAT QQYGRPGVT A27
1 RASQSVSSSYLA DASNRAT QQRSDWPRT L6
1 RASQSVSSSYLA SASSRAT QQHGSSPYT A27
1 TGTSSDVGGYNCVS DVTKRPS QSYDGSNHAV V1-3
1 RTSQSIYRYLN AVSSLQT QQLKSYPRIT 02
Ten total clones were sequenced. Clones not shown contained only a light chain.
tTen total clones were sequenced. Clones not shown contained only a light chain or had a duplicate
heavy chain and a new light chain.
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# of
clones
original
4
1
1
1
1
1
1
# of
clones
original
1
1
1
1
1
1
1
1
-
-
Biotin
Necessary
&
sufficient
for rolling
SO3 - SO3 - SO3
sLex lotlun
Enterokinase
cleavage site
Human Fc
Figure 3.1: The b.19.ek.Fc construct. This construct contains the N-terminal nineteen
amino acids of PSGL-I that have been determined to be necessary and sufficient for
rolling. These nineteen amino acids contain three sites of tyrosine sulfation and one site
of O-linked glycosylation. Two of these peptides are fused to a human Fc. An
enterokinase cleavage site allows for the isolation of the monovalent peptide.
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Figure 3.2: Bivariate histograms showing round by round affinity maturation. The
numbers in the upper right comer of each histogram indicate the percentage of double
positive clones. (A) Best clone from round 0, 800 nM divalent PSGL-1. (B) Best clone
from round 1, 800 nM divalent PSGL-1. (C) Best clone from round 1, 50 nM divalent
PSGL-1. (D) Best clone from round 2, 50 nM divalent PSGL-1. (E) Best clone from
round 2, 50 nM monovalent PSGL-1. (F) Best clone from round 2, 0.5 nM monovalent
PSGL-I. (G) Best clone from round 3 RR1 library, 0.5 nM monovalent PSGL-I. (H)
Best clone from round 3 RR2 library, 0.5 nM monovalent PSGL-1. (I) Best clone from
round 3 receptor editing library, 0.5 nM monovlanet PSGL-1. (J) Best clone from round
3 mutagenic library, 0.5 nM monovlanet PSGL-1.
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Round Schematic Representation Kd
Divalent PSGL-1 Monovalent PSGL-1
Round 0
Lead Isolation >5IV > 12MV
Round 1
Receptor Editing + Random _-12
Mutagenesis 1-5M 5 - 12/M
Round 2
Random Mutagenesis 90 + 110 pM 50 + 30 nM
Round 3
Random Mutagenesis
Receptor Revision with VHFR1 + VHCDR1
Preferentially Exchanged
Receptor Revision with VHFR1, VHCDR1,
VHFR2, VCDR2 Preferentially Exchanged
Receptor Editing
*. _
not determined 180 ± 100 pM
not determined 220 ± 200 pM
not determined 70 ± 60 pM
no improvement over previous round
* Indicates an insertion mutation, black bars indicate point mutations.
Figure 3.3: Round by round schematic of affinity maturation methodology with
best clone Kd values for anti-PSGL-1 antibodies. A pool of antibodies was
isolated in Round 0 and affinity matured over at least five orders of
magnitude in three library construction and screening steps to lead to the
generation of three different subnanomolar binders as measured by
titration with monovalent PSGL-1 on the surface of yeast.
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Figure 3.4: Histograms demonstrating the specificity of rls6-15. Percentages refer to the
percent of clones within the region specified on each histogram. (A) Binding of rls6-15
to 50nM of b.19.ek.Fc. (B) Decreased binding of rls6-15 to 50 nM of b.19.ek.Fc in the
presence of a 10 fold excess of KPL1. (C) Binding of rls6-15 to 50nM of b.19.ek.Fc in
the presence of 500 nM of an anti-enterokinase monoclonal antibody. (D) Binding of
rls6-15 to 100nM of b.19.ek.Fc. (E) Binding of rls6-15 to 100 nM of b.19.ek.Fc in the
presence of a 30 fold excess of human Fc.
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Figure 3.5: Schematic representation of mutagenesis strategies. (A) VHFR + VHCDR1
are preferentially exchanged (RR1 library). (B) VHFR1, VHCDR1, VHFR2, VHCDR2 are
preferentially exchanged (RR2 library). (C) Shuffling of the light chains (RE library).
The red and pink regions represented the antibody CDRs while the blue and brown
regions represented the antibody framework regions. The light green region in the center
of each PCR fragment is the (gly4ser)3 linker. The gray regions on the 5' or 3' end of the
PCR fragments indicate homology to the cut yeast surface display vector.
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A. C.
Figure 3.6: Representation of the electrostatic potential at the surface of clone RR2r3s4-
1 (top-down view). The heavy chain is shown on the left and the light chain is shown on
the right. Blue indicates regions of positive charge and red indicates regions of negative
charge. Residues referred to in purple text are mutations introduced during affinity
maturation. Residues referred to in yellow text are germline mutations that were present
in the starting antibodies prior to affinity maturation. Residues referred to in green text
are residues that are positively charged but are not germline mutations or mutations
introduced during the affinity maturation.
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Antigen-binding sites
Figure 3.7: Theoretical representation of the movements in sequence space caused by
receptor revision (reprinted from George and Gray).5 8 The x-axis shows all possible
binding sites with the most similar adjacent to one another. The affinity for a given
antigen is shown on the y-axis. An antibody starting at point A can only move toward the
local optimum point A' through point mutation. Receptor revision allows for large jumps
in sequence space that are usually detrimental (a movement to point B on the graph) but
sometimes lead to a new location (point C) that is nearer to a local optimum of higher
affinity (point C') than the optimum closest to the starting point.
69
Chapter 4: Characterization of a Novel High
Affinity Antibody Against PSGL-1
4.1 Introduction
We have developed a high affinity, fully human IgG directed against the N-
terminal nineteen amino acids of P-selectin glycoprotein I (PSGL-1). PSGL-1 binds to
P-selectin, a member of the selectin family of adhesion receptors which mediate the
initial rolling of leukocytes on the lumenal surfaces of the vascular endothelium7 5.
Although many glycoproteins have been shown to support rolling in vitro, PSGL-1 is the
only glycoprotein to be identified that has a clearly defined role as a physiological ligand
for P-selectin23' 28. The N-terminal nineteen amino acids of PSGL-l have been shown to
be both necessary and sufficient to mediate attachment and rolling on P-selectin in vivo24 .
Selectin mediated rolling is a particularly attractive target for therapeutic intervention
because it occurs early in the inflammatory cascade before firm adhesion and
extravasation into the surrounding tissue7 6. Blocking selectin binding may reduce tissue
damage by both decreasing the number of leukocytes that enter the surrounding tissue
and reducing the quantity of pro-inflammatory cytokines that are released. The search for
high affinity antagonists of selectin adhesion as therapeutics for acute and chronic
inflammation and ischemia-reperfusion injury states has been termed one of the Holy
Grails of the selectin field23.
Blocking of P-selecton-PSGL- interactions has been shown to be therapeutically
effective in several studies. A rat monoclonal antibody directed against the N-terminal
19 amino acids of mouse PSGL-I inhibited neutrophil recruitment into chemically
inflamed mouse peritoneum by 82% + 7% two hours after stimulation and 59% 7.9%
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four hours after stimulation77. A recombinant PSGL-1-Ig chimera (rPSGL-1-Ig)
consisting of the first 47 amino acids of the N-terminal portion of PSGL-1 fused to a
human IgGI Fc has been generated as a therapeutic by Wyeth and has proven to be
therapeutically effective in animal trials. For example, rPSGL-1-Ig has been shown to
accelerate thrombolysis and prevent reocclusion in a porcine model7 8, to attenuate
leukocyte-endothelial interactions after hemorrhagic shock in mice79, and to protect
against ischemia/reperfusion injury in cats80.
The disadvantage of rPSGL-1-Ig is its low affinity which is equal to that of
PSGL-1 for P-selectin (Kd = 320 20 nM)26. An alternative method of blocking P-
selectin-PSGL-I interactions is the use of monoclonal antibodies which can have their
affinity increased through various engineering techniques. High affinity therapies are
advantageous because they can be used in lower dosages that both reduce the risk of
harmful side effects and decrease cost. Although mouse derived monoclonal antibodies
directed against PSGL-1 such as KPLI, PLI and PL2, are known71 ' 81, they are not
suitable as therapeutics because of immunogenicity issues. Currently, only one human
monoclonal against PSGL-1 has been published8 2. This antibody, which is property of
Wyeth, does not have a published Kd.
In this paper we characterize the binding properties of a high affinity IgG, called
RR2r3s4-1, and a weaker affinity parent IgG, called r2s4-2. Both of these IgGs were
converted from scFvs (Figure 4.1) that had been engineered to high affinity from a pool
of anti-PSGL-1 binders (see Chapter 3) isolated from a yeast surface displayed non-
immune library'7 . The KdS were measured using tryptophan quenching titration. The
antibody RR2r3s4-1 was verified to bind neutrophils by flow cytometry. In addition,
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these antibodies were compared to the mouse monoclonal antibody KPL in both an
ELISA and a neutrophil rolling inhibition assay using a parallel wall flow chamber. To
our knowledge, RR2r3s4-l is the most effective antibody at inhibiting P-selectin-PSGL-I
interactions known.
4.2 Materials and Methods
4.2.1 IgG Production
The human IgGs used in this paper contain the variable heavy and variable light
regions from scFvs that have been described previously. The variable heavy and variable
light chain DNA was cloned into an IgGl heavy chain vector and a K light chain vector
both generously provided by Wyeth (Cambridge, MA). IgGs were produced in T 175
flasks using COS cells (Wyeth, Cambridge, MA). For each T1 75, COS cells were grown
in 30 mls of DME plus 10% heat inactivated fetal bovine serum (Sigma, St. Louis, MO)
plus mM glutamine plus 100 IU/ml penicillin (Mediatech, Herndon, VA) plus 100
,ug/ml streptomycin (Mediatech, Herndon, VA). Trypsin was used to make the adherent
COS cells soluble in the growth media each time cells were spilt. Cells were split I to 2,
grown for three days, then split to 3 and grown for two days. After the growth phase
cells were transfected with DNA using the follwing protocol. For each T175 flask, 7.0
ml of Opti-MEM media supplemented with glutamine was mixed with 125 ul of TransIT
(Mirus, Madison, WI), vortexed and incubated for 15 minutes at room temperature.
While incubating, 25 ug of heavy chain and 25 ug light chain DNA were mixed. After
incubation the DNA was added to the Opti-MEM (Invitrogen, Carlsbad, CA) plus
TransiT, mixed gently by pipeting, and incubated for 15 minutes at room temperature.
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This mixture was added slowly dropwise to the T175 containing the COS cells and
growth media. The next day the cells were rinsed twice with sterile PBS and 30 ml of
serum-free media (Wyeth, Cambridge, MA) media plus mM glutamine plus 100 IU/ml
penicillin plus 100 ug/ml streptomycin was added. After 48 hours the first harvest was
collected, spun in 250 ml conical bottles, and filtered through a 0.2 uM filter. Another 30
ml of serum-free media plus glutamine plus penicillin plus streptomycin was added and
72 hours later the same harvesting procedure was repeated.
4.2.2 IgG Purification
An HPLC (Millipore, Billerica, MA) was used to load a recombinant protein A
HiTrap FF I ml column (Amersham Biosciences, Piscataway, NJ). Before loading, the
harvests were pooled and 1/10 volume 5M NaCl was added and the sample was filtered.
Loading was done at 40C overnight. After loading the column, 10 ml of PBS was run
through the column. The elution was performed on an FPLC (Amersham Biosciences,
Piscataway, NJ) and the sample was concentrated and buffer exchanged into PBS using a
Centriprep YM-10 (Millipore, Billerica, MA). The concentration was determined by
taking the OD280 using an extinction coefficient of 1 OD2 80 = 1.4 mg/ml.
4.2.3 Tryptophan Fluorescence Quenching Titration
Kds were determined using an Eclipse fluorescence spectrophotometer (Varian,
Palo Alto, CA). Between each measurement, the 3 ml quartz cuvette was thoroughly
cleaned with 5M HNO3. Antibodies were diluted into PBS at a concentration of 20 nM.
The ligand used was a monovalent form of 19.ek.Fc called 19.ek (which was a kind gift
from Gray Shaw, Wyeth, Cambridge, MA) which lacks the Fc portion but does contain
the N-terminal 19 amino acids of PSGL-1. A stock of 15 uM 19.ek was prepared and
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added stepwise I ul at a time to the diluted antibody in the cuvette to give points that
differed by 5 nM in the ligand concentration. The cuvette was rotated end over end five
times to ensure proper mixing. The excitation and emission wavelengths were 290 nm
and 340 nm, respectively, and the excitation and emission slits were both set to 5 nm.
The PMT voltage was set to high.
4.2.4 Inhibition ELISA
A clear 96-well ELISA plate (Coming, Acton, MA) was coated with human P-
selectin (which was a kind gift from Diane Sako, Wyeth, Cambridge, MA) at a
concentration of I pug/ml, 100 p1 per well, overnight at 4C. The buffer for coating
consisted of 10 mM MOPS, 150 mM NaCl, I mM CaCl 2, 1 mM MgCl 2, pH 7.5. All
dilutions and washes were performed with the coating buffer plus 0.05% Tween 20. The
blocking buffer was the diluent/wash buffer plus 0.1% gelatin (Bio-Rad, Hercules, CA).
Blocking was performed with 200 pul blocking buffer per well, shaking, at room
temperature for one hour. In a separate, U-bottom, polypropylene plate called dilution
plate 1, a standard curve was made in duplicate by diluting a starting concentration of 
,ug/ml (4X final concentration) of a biotinylated form of 19.ek.Fc, called b. 19.ek.Fc (a
gift of Dr. Raymond T. Camphausen, formerly of Wyeth, Cambridge, MA), serially 1 to
3 leaving 60 ,ul per well. The 19.ek.Fc protein contains the 19 N-terminal amino acids of
PSGL-1 and has been described previously 24. Column three of the plate received 60 pul
per well diluent buffer. For the remaining columns, 60 ul per well of b.19.ek.Fc were
aliquoted at 80 ng/ml (4X final conentration). To all wells on dilution plate 1, 60 ,ul of a
I to 500 dilution of streptavidin-HRP (Pierce, Rockford, IL) was added. Dilution plate 1
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was incubated at room temperature for thirty minutes in order to pre-complex the
b. 19.ek.Fc to the streptavidin-HRP.
To the first four columns of a U-bottom, polypropylene plate called dilution plate
2, 80 Al1 of diluent buffer were added. Antibodies were started in duplicate at a
concentration of 1.5 uig/ml and diluted twofold. The KPLI antibody was obtained from
BD Pharmingen (San Diego, CA) and a negative isotype matched human IgG, control
was generously provided by Wyeth (Cambridge, MA). After pre-complexing has been
completed in dilution plate 1, 80 Al per well were transferred from dilution plate 1 to
dilution plate 2 and incubated at room temperature for fifteen minutes. After this
incubation, 100 ul per well were transferred to the blocked P-selectin coated plate and
incubated at room temperature for thirty minutes. The plate was then washed five times
and 100 ul of pre-warmed TMB (BioFx, Owings Mills, MD) was added to each well and
incubated at room temperature for between ten and fifteen minutes. To stop the reaction,
100 A1 of 0.18 M H2 S0 4 was added to each well. The absorbance was read on a
Molecular Devices UVMax plate reader at 450 nm.
4.2.5 Fluorescence Staining for Flow Cytometry
Neutrophils were isolated in the following manner. Whole blood was mixed 4 to
1 with 4.5% dextran in 0.9% NaCl. The mixture was left to settle for 90 minutes at room
temp. The top clarified fraction was collected and washed in sterile PBS. After spinning,
the pellet was resuspended in the small fraction of liquid left over after pouring off the
PBS. Red blood cells were lysed by adding 9 mls of water, letting the cells sit in the
water for I to 2 minutes, then adding 1 ml of 10X Hanks' balanced salt solution. Next,
the cells were washed with PB then resuspended in PBS and counted using a
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hemocytometer. Cells were analyzed within I to 2 hours of the completion of the
neutrophil isolation.
Approximately 250000 cells were labeled. PBS plus 0.1% BSA was used as the
dilution and wash buffer. The primary antibodies were biotinylated using an EZ-Link
sulfo-NHS biotin (Pierce, Rockford, IL). Primary labeling was performed on ice for 30
minutes at a concentration of 10 ,ug/ml (66.7 nM). After washing, cells were labeled with
streptavidin-R-phycoerythrin (strep-PE) (Molecular Probes, Eugene, OR) at a dilution of
1 to 200 for 30 minutes on ice. The cells were then washed and were suspended in 180
/pl of PBS plus 0.1% BSA plus 20 ul of 7-amino-actinomycin-D (7AAD) (BD
Pharmingen, San Diego, CA) and incubated for 15 minutes on ice. Windows were drawn
using the 7AAD to gate out dead cells. Analysis was performed on a FACSCalibur (BD
Biosciences, San Jose, CA).
4.2.6 Rolling Inhibition Assay
Polysterene plates were adsorbed with 10 pg/ml of soluble recombinant P-selectin
(R & D Systems, Minneapolis, MN) in PBS, supplemented with 10 mM bicarbonate, pH
9 at 4C for 16 hours, washed with PBS, pH 9, blocked with PBS/2% human serum
albumin (HSA) at 4C for 2 hours, and washed with PBS, pH 9. Substrates were
assembled on the lower wall in a parallel wall-flow chamber and mounted on an inverted
phase-contrast microscope. Human neutrophils were isolated as previously described8 3
and resuspended in Hanks' balanced salt solution supplemented with 10 mM Hepes, pH
7.4 (H/H) containing 2 mM Ca2+, 0.5 % BSA. Neutrophils were perfused through the
flow chamber at I x 106 cells/ml at 0.3 dyne/cm 2 for 30 s and 1.0 dyne/cm2 for 2 min.
For the blocking assays, 1 x 106 neutrophils in 50 ul were first incubated with the various
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antibodies at 10, 2, 1, 0.5, and 0.1 ug/ml for 10 min at room temperature, and the volume
was increased to 1 ml with H/H containing 2 mM Ca2+, 0.5% BSA. Microscopic images
of cells under flow were recorded on Hi-8 videotape using a Nikon plan O1X-objective
microscope. Analysis was performed with a computerized imaging system consisting of
a Pentium computer with MVC 150/40-VL boards (Imaging Technology, Bedford, MA).
The isotype matched negative control antibody was provided by Wyeth (Cambridge,
MA) and the PL2 antibody was obtained from Immunotech (Marseille, France).
4.3 Results
4.3.1 Determination of Dissociation Constant (Kd)
The dissociation constant for r2s4-2 and RR2r3s4-1 were determined by
tryptophan fluorescence quenching titration. This method involves the measurement of
the decrease in fluorescence of a known quantity of antibody (in this case 20 nM) by the
sequential addition of a given quantity of antigen (5 nM per datapoint). The following
equation can be used to fit the data:
FE -FL 4.1F =FE -[(ET +LT + K)- (ET +LT + K) 2 -4ETLT -F 4.1
where F is the observed fluorescence, LT is the ligand concentration, ET is the total
antibody concentration, FE is the observed fluorescence without any ligand, and FEL is the
observed fluorescence intensity of the antibody-ligand complex at infinite ligand
concentration 8 4 .
For each clone three replicates were performed. Using this method, the best fit Kd
for r2s4-2 is 6.2 ± 3.0 nM and the best fit Kd for RR2r3s4-1 is 1.8 + 0.7 nM (examples of
one curve fit for each clone are shown in Figure 4.2). These Kds differ from those
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determined in Chapter 3. The Kd, for r2s4-2 is about seven fold stronger and the Kd for
RR2r3s4-1 is about twenty-seven fold weaker. This difference is due to the reformatting
and may be because the constant regions of the IgG orient the domains in the variable
region slightly differently than they are oriented in an scFv format.
4.3.2 Binding of RR2r3s4-1 to Human Neutrophils
The antibody RR2r3s4-1 was raised against an artificial construct, b. 19.ek.Fc, that
contains only the terminal nineteen amino acids of PSGL-1. It is important to
demonstrate that this antibody binds to the physiologically relevant protein which is
PSGL- 1 expressed on the surface of human neutrophils. Figure 4.3 shows that 67 nM of
biotinylated RR2r3s4-1 binds to human neutrophils while a biotinylated, isotype matched
negative control antibody does not.
4.3.3 Inhibition ELISA
One way to compare the blocking effectiveness of the two antibodies presented in
this paper with the previously characterized antibody KPL1 is to demonstrate each
antibody's ability to inhibit the binding of b. 19.ek.Fc to a P-selectin coated ELISA plate.
The basic setup of this experiment is shown in Figure 4.4A. To determine the optimum
concentration of b. 19.ef.Fc for inhibition, a standard curve was made by serially diluting
b.19ek.Fc that has been pre-complexed with strep-HRP. In order to determine binding
inhibition, the signal for binding of the b. l19.ek.Fc to P-selectin in the absence of antibody
must not be too high or the detector will be saturated and must not be too low or the
differences in signal caused by inhibition will be too small to measure. The curve shown
in Figure 4.4B indicates why the optimal labeling concentration of b.19.ek.Fc is
approximately 20 nM. This concentration is near the saturation limit of the detector but
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does not exceed this limit thus differences in b. 19.ek.Fc binding to P-selectin can be
measured. The inhibition constants can be determined by fitting the data to the following
equation:
Y = Bmax l- Xn + Y2 4.2
where Y is the absorbance at 450 nM, x is the inhibitor concentration, Ba,, is the
maximum absorbance in the absence of inhibitor, K is the IC50, Y2 is the absorbance at
maximal inhibition, and n is a factor that allows for the adjustment of the slope of the
curve at the value of the IC50.
Figure 4.4C shows the results. RR2r3s4-1 has the lowest IC50, and thus is a
better inhibitor of P-selectin adhesion to PSGL-1 than KPL 1. As expected, r2s4-2 has the
largest IC50 and therefore is the poorest inhibitor. It is important to mention that the
actual value of the IC50s in this experiment only have meanings within the context of this
inhibition ELISA. They measure inhibition of a multivalent entity from binding to a
multivalent surface and must not be confused with Kd values.
4.3.4 Rolling Inhibition
The ability of various antibodies to inhibit neutrophil rolling is shown in Figure
4.5. This in vitro rolling experiment was performed in a parallel plate flow chamber.
Since it is possible for cells to form a transient tether, then detach and not roll it is
necessary to define the difference between cells that form transient tethers and cells that
actually roll. The definition we used for tethering and rolling is as follows: "transient
tethers, cells that attached briefly to the substrate without rolling motions, and rolling
tethers, cells that remained rolling on the substrate, i.e. moving at a mean velocity not
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more than a fourth the hydrodynamic velocity for at least three seconds after initial
tethering." 85
As Figure 4.5 shows, RR2r3s4-1 has near 100% inhibition at a concentration of
3.3 nM while KPL1 has lost nearly half of its ability to inhibit neutrophil rolling at this
concentration. The lower affinity antibody, r2s4-2, loses all of its ability to inhibit
neutrophil rolling at 3.3 nM. The control antibodies named "negative" and PL2 barely
inhibit rolling at all at the highest concentration tested, 66.7nM. The "negative" antibody
is an isotype matched antibody and its non-binding indicates that the binding site of the
antibodies that do inhibit is necessary for inhibition. PL2 is an antibody that binds
PSGL- but does not bind in the site that is necessary and sufficient for neutrophil rolling
and was added as an addition control. The PL2 data is important because it shows that it
is possible to bind to the neutrophils but not block rolling. Only antibodies that bind in
the terminal nineteen amino acids will have the desired inhibitory effect. The rolling
inhibition data demonstrates that RR2r3s4-1 is the best antibody at inhibiting neutrophil
rolling that has yet been characterized. This data, in conjunction with the flow cytometry
data, indicates that RR2r3s4-1 binds to PSGI,-1 and this binding is within the epitope that
is necessary and sufficient for neutrophil rolling.
4.4 Discussion
The paper demonstrates that a novel antibody, RR2r3s4-1, that has been isolated
form a yeast surface displayed non-immune human library and engineered for high
affinity binding to PSGL-1, has therapeutic potential. It binds to the correct cell type and
blocks these cells from rolling in an in vitro flow assay. This inhibition is better than the
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commercially available mouse monoclonal KPL 1. Two assays, the rolling assay and an
inhibition ELISA, demonstrate that this antibody inhibits binding of P-selectin to PSGL- 1
better than KPL1. The only other human antibody, owned by Wyeth, does not have
published characterization information therefore until this information is published,
RR2r3a4-1 is the best inhibitor of P-selectin/PSGL- 1 binding known.
The next step is to perform a tissue cross reactivity assay in order to determine the
specificity of RR2r3s4-1. If the antibody does not show significant cross reactivity,
animal studies must be performed to see if there is a therapeutic effect. Hopefully, this
antibody will become a major weapon in the ongoing fight against acute and chronic
inflammatory conditions.
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scFv IgG
Yeast Expression COS Expression
Figure 4.1: Conversion of an scFv to an IgG. The svFv contains only the variable
region of an IgG and is monovalent. In an IgG, two identical variable regions are present
making the molecule divalent. In this chapter, the IgGs are produced in COS cells, which
are a mammalian cell line. This production system is different from the yeast expression
system used to make the scFvs described in Chapter 3.
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Figure 4.2: Fluorescence quenching titrations. (A) Example of
r2s4-2. (B) Example of one titration of clone RR2r3s4-1.
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Figure 4.3: Binding of RR2r3s4-1 to human neutrophils. The red line indicates the
histogram of the binding of 67 nM of biotinylated RR2r3s4-1 to human neutrophils. The
blue line indicates the lack of binding of 67 nM of an isotype matched negative control
antibody.
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Figure 4.4: Inhibition ELISA. (A) Schematic of the inhibition ELISA setup. Strep-
HRP is pre-complexed with b. 19.ek.Fc. This complex can be prevented from binding to
a P-selectin coated ELISA well by the presence of anti-PSGL-1 antibodies. (B) The
optimal concentration for inhibition can be determined by making a standard curve for
the binding of pre-complexed b. 19.ek.Fc-strep-HRP to P-selectin coated wells. (C) Bar
graph showing the inhibition constants (IC50) for RR2r3s4-1, KPLI, and r2s4-2.
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Figure 4.5: Percent of neutrophils inhibited from rolling by various antibodies. The
antibody PL2 is a mouse monoclonal antibody that binds PSGL-1 but does not bind in the
sight that is responsible for P-selectin binding. At the lowest concentration tested, 1.7
nM, none of the antibodies inhibited neutrophil rolling. The most potent rolling inhibitor
was RR2r3s4-1 which blocked virtually 100% of cells rolling at a concentration of 3.3
nM.
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Appendix A: Amino Acid Sequence
Divergence of Isolated Clones
from Framework Sequence
rls6-15 scFv Amino Acid Sequence
Sequence (red letters indicate divergence from framework sequence)
VFR1
QVQLQQSGPGLVKPSQTLSLTCAISGDSVS
QVQLQQSGPGLVKPSQTLSLTCAISGDSVS
VHCDR1
SNNVAWN
SNSAAWN
VHFR2
WIRQSPSRGLEWLG
WIRQSPSRGLEWLG
VHCDR2
RTYYRSKWYNDYAA SVKS
RTYYRSKWYNDYAVSVKS
VHFR3
RIT1N . DTSKNQFSL HLNSVTPEDTAVYYCTR
RITINPDTSKNQFSLQLNSVTPEDTAVYYCAR
Variable Chain Name
VH6-01 FRI
VH6-01 CDRI
VH6-01 FR2
VH6-01 CDR2
VH6-01 FR3
V HCDR3
GGGRAQSA
VHFR4
WGQGTLVTVSS
(Gly4Ser)3 Linker
GGGGSGGGGSGGGGS
GGGGSGGGGSGGGGS
VLFR1
EIVLTQSPGTLS \'SPGERATLSC
EIVLTQSPGTLSLSPGERATLSC VKIII 6-1-(1) A27 FRI
VLCDRI
RASQSVSRSHLA
RASQSVSSSYLA
VLFR2
WYQQKPGQAPRLLIF
WYQQKPGQAPRL.LIY VKIII 6-1-(1) A27 FR2
VLCDR2
GASSRAT
GASSRAT VKlll 6-1-(1) A27 CDR2
VLFR3
GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC
GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC VKIII 6-.1-(l)A27 FR3
VLCDR3
QQYGS PVT
QQYGSSP
VLFR4
FGQGTKVEIK
VKfll 6-1-(1) A27 CDR3
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Vvt4I 6-1 -(I) A27 CDR I
r2s4-2 scFv Amino Acid Sequence
Sequence (red letters indicate divergence from framework sequence)
VuFRI
QVQLQQSGPGLVKPSQTLSLTCAISGDSVS
QVQLQQSGPGLVKPSQTLSLTCAISGDSVS
VHCDR1
SNNVAWN
SNSAAWN
VHFR2
WIRQSPSRGLEWLG
WIRQSPSRGLEWLG
VHCDR2
RTYYRSKWYNDYAASVKS
RTYYRSKWYNDYAVSVKS
VHFR3
RITIN \DTSKNQFSL H LNSVTPEDTAVYYCTR
RITINPDTSKNQFSLQLNSVTPEDTAVYYCAR
Variable Chain Name
VH6-0 FRI
VH6-01 CDR I
VH6-01 FR2
VH6-01 CDR2
VH6 -01 FR3
VHCDR3
GGGRAHSA
VHFR4
WGQGTLVTVSS
(Gly4Ser)3 Linker
GGGGSGGGGSRGGGS
GGGGSGGGGSGGGGS
VLFR1
EIVLTQSPGTLS\SPGERATLSC
E[VLTQSPGTLSLSPGERATLSC VKII 6-1-(I) A27 FRI
VLCDR1
RASQSVSRSHLA
RASQSVSSSYLA VAII 6-1-(I)A27 CDRI
VLFR2
WYQQKPGQAPRLLI-
WYQQKPGQAPRLLIY VaIli 6-1-(1) A27 FR2
VLCDR2
GASSRAT
GASSRAT V-II 6-1-(1)A27 CDR2
VLFR3
GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC
GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC VA-I 6-1-(1)A27 FR3
VLCDR3
QQYGRPGiVT
QQYGSSP
VLFR4
FGQGTKVEIK
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VIII 6-1-(1)A27 CDR3
r3s4-3 scFv Amino Acid Sequence
Sequence (red letters indicate divergence from framework sequence)
VHFR1
QVQLQQSGPGLVKPSQTLSLTCAISGDSVS
QVQLQQSGPGLVKPSQTLSLTCAISGDSVS
VHCDR1
SNNVAWN
SNSAAWN
VHFR2
WIRQSPSRGLEWLG
WIRQSPSRGLEWLG
VHCDR2
RTYYRSKWYNDYAASVKG
RTYYRSKWYNDYAVSVKS
VHFR3
RITIN. DTSKNQFSLHLNSVTPEDTAVYYC-TR
RITINPDTSKNQFSLQLNSVTPEDTAVYYCAR
Variable Chain Name
VH6-01 FRI
VH6-01 CDRI
VH6-01 FR2
VH6-01 CDR2
VH6-01 FR3
VHCDR3
GGSRAHSA
VHFR4
WGQGTLVTVSS
(GIy4Ser)3 Linker
GGGGSGGGGSRGGGS
GGGGSGGGGSGGGGS
VLFRI
EIVLTQSPGTLS\!SPGERATLSC
EIVLTQSPGTLSLSPGERATLSC V,ll 6-1-(I) A27 FRI
VLCDR1
RASQSVSRSHLA
RASQSVSSSYLA
VLFR2
WYQQKPGQAPRLLIF
WYQQKPGQAPRLLIY VKIIl 6-1-(1) A27 FR2
VLCDR2
G\VSSRAT
GASSRAT VKIll 6-1-(1) A27 CDR2
VLFR3
GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC
GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC Vlll 6-1-(I) A27 FR3
VLCDR3
QQYGRPG VT
QQYGSSP
VLFR4
FGQGTKVEIK
VKTII 6-1-(1)A27 CDR3
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VIII 6-1-(I) A27 CDR]
RRlr3s4-2 scFv Amino Acid Sequence
Sequence (red letters indicate divergence from framework sequence)
VHFR1
QVHLQQSGPGLVKPSQTLSLTCAISGDSIS
QVQLQQSGPGLVKPSQTLSLTCAISGDSVS
VHCDRI
SNTAAWN
SNSAAWN
VHFR2
WIRQSPSRGLEWLG
WIRQSPSRGLEWLG
VHCDR2
RTYYRRSKWYNDYAASVKS
RTYYRSKWYNDYAVSVKS
VHFR3
RITINA\DTSKNQFSLHLNSVTPEDTAVYYCTR
RITINPDTSKNQFSLQLNSVTPEDTAVYYCAR
Variable Chain Name
VH6-01 FRI
VH6-01 CDRI
VH6-01 FR2
VH6-01 CDR2
VH6-01 FR3
VHCDR3
GGGRAHSA
VHFR4
WGQGTLVTVSS
(Gly4Ser)3 Linker
GGGGSGGGGSRGGGS
GGGGSGGGGSGGGGS
VLFR1
EIVLTQSPGTLS VSPGERATLSC
EIVLTQSPGTLSLSPGERATLSC VKIII 6-1-(I)A27 FRI
VLCDR1
RASQSVSRSHLA
RASQSVSSSYLA VKIII 6-1-(1)A27 CDR1
VLFR2
WYQQKPGQAPRLLII:
WYQQKPGQAPRLLIY V,41I 6-1-(I) A27 FR2
VLCDR2
GASSRAT
GASSRAT VKIII 6-1-(1) A27 CDR2
VLFR3
GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC
G [PDRFSGSGSGT DFTLTISRLEPEDFAVYYC VxIIl 6-1-(1)A27 FR3
VLCDR3
QQYGRP(i VT
QQYGSSP
VLFR4
FGQGTKVEIK
VKIII 6-1-(I) A27 CDR3
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RR2r3s4-1 scFv Amino Acid Sequence
Sequence (red letters indicate divergence from frame,ork sequence)
VHFRI
QVQLQQSGPGL'VKPSQTLSLTCAISGDSVS
QVQLQQSGPGLVKPSQTLSLTCAISGDSVS
V HCDRI
SNIAAWII
SNSAAWN
'vHFR2
WIRLSPSRGLEWLG
WIRQSPSRGLEW'LG
VHCDR2
R.TYYRRSKWN ' DYALSVKS
RTYYRSKWYNDYAVSVKS
V'HFR3
R.INNPDTSKN LFSLQLNSVTPEDTAVYYCTR
RITINPDTSKNQI-SLQLNSVTPEDTAVYYCAR
Variable Chain Name
VH6-01 FRI
VH6-01 CDRI
VH6-01 FR2
VH6-01 CDR2
VH6-01 FR3
VHCDR3
GGGRAHSA
VHFR4
WGQGTLVTVSS
(Gly4Ser)3 Linker
GGGGSGGGGS RGGGS
CGGGGSGGGGSGGGGS
VLFRI
EIVLTQSPGTLSV'SPGERATLSC
EIVLTQSPGTLSIl SPGERATLSC V,III 6-1-(1)A27 FRI
N'LCDR1
RASQSVSRSH LA
RASQSVSSSYLA. VxIIJ 6-1-(1) A27 CDR1
V,,FR2
WYQQKPGQAPF'LLII:
WYQQKPGQAPF'LLIY VKII 6-1--(1) A27 FR2
XLCDR2
GASSRAT
GASSRAT VKIII 6-1-(1) A27 CDR2
VLFR3
C;GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC
GIPDRFSGSGSG'T'DFTLTISRLEPEDFAVYYC VK1II 6-1-(1) A27 FR3
VLCDR3
QQYGR P(.VT
QQYGSSP VKIII 6-1-(1)A27 CDR3
N'LFR4
FGQGTKVEIK
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Education
1999-2004 Massachusetts Institute of Technology Cambridge, MA
Ph.D. Department of Chemical Engineering, February 2005. Thesis:
Isolation and Engineering of a High Affinity Antibody Against P-selectin
Glycoprotein Ligand-1 (PSGL-1).
1995-1999 Princeton University Princeton, NJ
B.S.E. Department of Chemical Engineering, Summa Cum Laude. GPA:
3.95/4.0. Certificate in Engineering Biology. Senior Thesis: The Role of Electrostatics in
the Energetics of Interaction Between Proteins and Polymer Hydrogels.
Research Experience
MIT, Department of Chemical Engineering
Graduate Student (2000-2004)
Advisor: Professor K. Dane Wittrup
Cambridge, MA
· Isolated and engineered a novel human single chain antibody (scFv) for
use as a potential anti-inflammatory therapeutic using yeast surface
display, fluorescence activated cell sorting (FACS), and directed evolution
technology.
· Generated multiple high affinity antagonists of P-selectin adhesion.
· Engineered a large affinity improvement (at least 1 *105 fold)
· Developed a new method for the facile generation of large, shuffled
antibody libraries in yeast.
Wyeth Research, Antibody Technologies Group and
Cardiovascular and Metabolic Diseases Group
Summer Intern (2003 and 2004)
Supervisors: Gray D. Shaw and Angela Widom
Cambridge, MA
· Generated IgGs based upon the scFvs engineered in the Wittrup Lab.
· Characterized the binding properties of the IgGs using ELISA and
Biacore.
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Princeton University, Department of Chemical
Engineering
Summer Intern (1998)
Supervisor: Professor Jeffrey D. Carbeck
Princeton, NJ
Studied controlled release of proteins from polymer hydrogels.
Gained extensive knowledge in the use of capillary electrophoresis as a
tool to study modified proteins.
University of Pittsburgh Department of Chemical
Engineering
Summer Intern (1997)
Supervisor: Professor Alan J. Russell
Pittsburgh, PA
Increased the stability of organophosphorus hydrolase, an enzyme that
degrades nerve agents, in bleach.
Awards
2000-2004
1999-2000
1999
1998
NIH Biotechnology Training Grant Fellowship
Rosenblith Fellowship
Phi Beta Kappa
Richard K. Toner Thermodynamics Prize
Sigma Xi Scientific Honor Society
Tau Beta Pi Engineering Honor Society
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